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Introduction: Alzheimer’s disease (AD) is the most common form of irreversible 
dementia and characterized clinically by progressive deterioration of intellectual abilities, 
including cognitive and behavioral dysfunctions. Pathologically, AD is characterized by 
the extracellular deposits of amyloid-β peptides and aggregation of intraneuronal 
neurofibrillary tanglets. The degeneration of cholinergic neurons in the basal forebrain and 
the associated loss of the cholinergic neurotransmission in the cerebral cortex and other 
area contributed significantly to the deterioration in cognitive function in AD. Deficiency 
in high affinity choline uptake (HACU) and the loss of vesicular acetylcholine transporter 
(VAChT), are two characteristic neurochemical changes in AD. In cholinergic neurons, 
HACU by the high affinity choline transporter (HAChT) is a rate-limiting and regulatory 
step for the synthesis of Ach and VAChT mediates the loading of presynaptic vesicles with 
newly synthesized acetylcholine. Thus, both the HAChT and VAChT appear to be two 
relatively specific presynaptic marker for cholinergic neurons in AD brain.  
Objectives: This PhD thesis can be divided into two parts. The objective of PART A 
includes the syntheses and in vitro evaluation of MKC-231, tacirine and its corresponding 
2-oxo-1-pyrrolidineacetyl derivative as high affinity choline transporter imaging agent. The 
objective of PART B is to develop radiobromine labeled o-bromo-trans-decalinvesamicol 
(OBDV) as a potent and new PET radiotracer for VAChT imaging in AD brain through in 
vivo evaluation and ex vivo autoradiography.  
Methods: In PART A, the inhibition activities of tacirine, the 2,3-dimethylfuran derivative 
of tacirine (DMTA) and their corresponding 2-oxo-1-pyrrolidineacetyl derivatives, namely 
PTAA and MKC-231 were measured by displacement of a typical HAChT antagonist 
[3H]HC-3 (Dissociation constant: Kd = 19.1 nM) in rats cerebral membrane. The percent 
inhibition against the binding of [3H]HC-3 to HAChT were calculated using GraphPad 
Prism v4 software. In Part B, in vivo evaluation of [77Br]OBDV was performed instead of 
2[76Br]OBDV, because of the longer half-life of 77Br (t1/2 = 57.0 h). [
77Br]OBDV was 
radiosynthesized by the tin-bromine exchange reaction from trimethylstannyl precursor, 
o-trimethylstannyl-trans-decalinvesamicol (OTDV). In vivo biodistribution study of 
[77Br]OBDV in blood, brain regions and major organs of rats was performed at 2,30 and 60
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min post-injection. In vivo blocking study was performed to check the binding selectivity 
of [77Br]OBDV for VAChT. In vivo metabolism of [77Br]OBDV in the blood and brain of 
SD rats at 60 min post-injection was examined using TLC. Ex vivo autoradiography was 
performed to reveal the regional brain distribution of [77Br]OBDV at 30 min post-injection. 
Results:  In PART A, only HC-3 showed affinity for HAChT (IC50 = 20 nM) in the in 
vitro binding assay. A very insignificant inhibition activity (IC50 = 1000 nM) of Tacrine was 
revealed. The newly synthesized tacirine derivatives, DMTA and PTAA did not show any 
affinity for HAChT. Although MKC-231 was reported to enhance cholinergic activity at 
synaptic terminals, it also did not show any affinity for the HAChT in [3H]HC-3 binding 
assay. Other inhibitors like choline chloride (ChCl), Acetylcholine chloride (AChCl), 
Carbamylcholine Chloride (CaChCl) showed no binding affinity for HAChT. In part B, 
[77Br]OBDV was radiosynthesized with radiochemical purity of greater than 99%, and the 
radiochemical yield was 52.3 ~ 65.8%. The specific activity (SA) of [77Br]OBDV was 
found to be 322 ~ 406 GBq/μmol. At 2 min post-injection time, the uptake of [77Br]OBDV 
in blood and brain regions was found 0.14 ± 0.01%ID/g and 0.62 ± 0.7 %ID/g respectively, 
which confirmed blood-brain barrier penetration of [77Br]OBDV. In in vivo biodistribution 
studies, at 30 min post-injection, the accumulation of [77Br]OBDV in cerebral cortex, 
striatum and cerebellum of the rat brain was 0.52 ± 0.11 %ID/g, 0.59 ± 0.05 %ID/g and 
0.56 ± 0.04 %ID/g respectively. In in vivo blocking studies, (+/-)-vesamicol blocked 
regional brain uptake of [77Br]OBDV by 41%. In contrast, no blocking effects were 
observed by both the (+)-3-PPP (σ1, σ2 receptor ligand) and (+)-pentazocine (σ1 receptor 
ligand). In ex vivo autoradiography, accumulation of [77Br]OBDV was observed in VAChT 
rich brain regions, such as the cerebral cortex, diagonal band, hippocampus, posterolateral 
cortical amygdaloidal nucleus. 
Conclusion: In Part A, in vitro [3H]HC-3 binding assay revealed no affinity of MKC-231, 
tacirine and its corresponding 2-oxo-1-pyrrolidineacetate derivative towards HAChT. So, it 
is worthy to develop radiolabeled HC-3 derivatives with high affinity for HAChT, which 
can diffuse the BBB, to enable the in vivo investigation of HACU system. In Part B, In vivo 
results showed that [77Br]OBDV selectively bound to VAChT with high affinity in rat 
brain in vivo. Hence, OBDV radiolabeled with 76Br was suggested to be a potent VAChT 
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OTDV  ortho-trimethylstannyl-trans-decalinvesamicol 
PDH  Pyruvate dehydrogenase 
PET  Positron Emission Tomography 
P-gp   P-glycoprotein 





PP-1   Protein phosphatase 1  
PP-2A  Protein phosphatase 2 
PS   Phosphatidylserine  
PTAA  2-(2-Oxo-pyrrolidin-1-yl)-N-(1,2,3,4-tetrahydro-acridin-9-yl) 
-acetamide 
(+)-3PPP   3-(3-hydroxyphenyl)-N-n-propylpiperidine 
Pyr  Pyruvate 
RRC   Relative radioactivity concentration 
SFs   Straight filaments 
SD rat   Sprague Dawley rat 
SPECT  Single Photon Emission Computed Tomography  
THA  9-amino-1,2,3,4-tetrahydroacrydine (Tacirine) 
TLC   Thin Layer Chromatography 
VAChT  Vesicular Acetylcholine Transporter 
VAChT-IR  Vesicular Acetylcholine Transporter -immunoreactive axon   
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1.1  Alzheimer’s disease:  
Alzheimer's disease (AD), also called as Senile Dementia of Alzheimer type 
(SDAT), is a progressive neurologic disease of the brain leading to the irreversible loss 
of neurons and the loss of intellectual abilities, including memory and thinking, which 
become severe enough to hamper social or occupational functioning. This 
neurodegenerative disease is named after the German psychiatrist Alois Alzheimer, who 
first described it in 1906. It is a disorder of the gray matter of the cerebral cortex and 
generally diagnosed in people over 65 years (Brookmeyer R et al., 1998) of age, but the 
less-prevalent early-onset Alzheimer’s can also occur much earlier. Clinically, the 
disease is characterized by progressive dementia and pathologically by the extracellular 
deposition of senile plaques and intraneuronal neurofibrillary tangles. AD starts in the 
entorhinal cortex and then progresses to the hippocampus, basal nuclei, and then to the 
neocortex. It spares primary motor and sensory cortices, preferentially attacking 
association areas in the frontal, parietal, and temporal lobes. Affected regions are 
associated with the neurochemical deficits of acetylcholine, glutamate, and serotonin 
and the degree of dementia correlates with the decline of these neurotransmitters, 
revealed in biopsy or autopsy tissue. Dementia is a clinical syndrome, which include 
memory disorder plus at least one other cognitive sign: language, motor or procedural 
memory (praxis), spatial function, and executive function (decision making, planning, 
and control of behavior) (Stephen S Flitman 2011). 
The disease course can be sub-divided into four stages (National institute of 
Aging 2007, Rizzo S 2009). Although the symptoms of AD in each individual patients 
are distinctive, there are some common symptoms with the progressive pattern of 
cognitive and functional deficiency (National institute of aging 2007, Rizzo S 2009).
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1.1.1 Predementia 
The most noticeable impairment is memory loss, which was expressed as 
difficulty in remembering the most recent events or facts and inability to gain new 
informations. Problems associated with the executive functions, such as attentiveness, 
scheduling, flexibility, and immaterial thinking, or impairments in sematic memory 
(memory of meaning, and concept of relationships), can also be symptoms at the early 
stage of AD.  
1.1.2 Early dementia 
The progressive impairment of learning and memory are two important clinical 
symptoms in AD. In a small proportion of AD patients, difficulties with language, 
executive functions, agnosia, or apraxia are more prominent than the impairment of 
learning and memory. In this stage, the person with AD is usually adequately capable of 
communicating basic ideas. While difficulties may be present in performing fine motor 
tasks, such as writing, drawing or dressing, coordination in certain movement, planning 
and ultimately the patient is appeared clumsy.  
1.1.3 Moderate dementia 
In this stage, speech difficulties become evident, which leads to paraphasias. 
Reading and writing skills are also progressively lost. As time passes, complex motor 
sequences become less coordinated and the ability to perform most normal daily living 
activities is reduced. In this phase, memory problems are worsen and the patients may 
not able to recognize close relatives. Long-term memory, which was previously intact, 
become impaired, and behavioral changes become more prominent.  
1.1.4 Advanced dementia 
Language is reduced to simple phrases or even single word, ultimately leading 
to the complete loss of speech. Despite the loss of verbal language ability, patients can 
                                     Chapter I: General Introduction 
3 
often understand and return emotional signals. Ultimately, patients will not be able to 
perform even the simplest tasks without the assistance from others. Finally comes death, 
usually caused directly by external factors such as pressure, ulcers, and pneumonia, not 
by the AD itself.  
1.1.5 Pathological hallmarks 
Although the origin of AD is still unknown, pathological hallmarks include 
neurofibrillary tangles (NFTs), amyloid-β plaques, neuropil threads, Hirano’s bodies, 
granulovacuolar bodies, cerebral amyloid angiopathy (Cvetkovic-dozic D et al., 2001) 
and synaptic loss. At autopsy, the AD brain is characterized by a number of important 
pathological changes, including a marked loss of neurons and synapses in many areas 
of the CNS, which include hippocampus, parahippocampus, and amygdala 
(Cvetkovic-dozic D et al., 2001). In addition, there is a reduction of neurotransmitters 
level, noradrenaline, dopamine, glutamate, substance P and acetylcholine (ACh) was 
also observed in AD. Among the neurotransmitters, ACh is the most important cause of 
the clinical manifestations of AD. 
1.1.6 Epidemiology of Alzheimer's disease 
Two main measures are used in epidemiological studies: incidence and 
prevalence. Incidence is the number of new cases per thousand person–years, while 
prevalence is the total number of cases of the disease in the population at a given time. 
1.1.6.1 Prevalence of Alzheimer’s disease 
The pooled data of population-based studies in Europe suggests that the 
age-standardized prevalence in people over 65 years old is 6.4% for dementia and 4.4% 
for AD (Lobo A et al., 2000). In the US, the study of a national representative sample of 
people aged over 70 years yielded prevalence for AD of 9.7% (Plassman BL et al., 
2007). Worldwide, the global prevalence of dementia was estimated to be 3.9% in 
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people aged over 60 years, with the regional prevalence being 1.6% in Africa, 4.0% in 
China and Western Pacific regions, 4.6% in Latin America, 5.4% in Western Europe, 
and 6.4% in North America (Cleusa P Ferri et al., 2005). More than 25 million people 
in the world are currently affected by dementia, most suffering from AD, with around 5 
million new cases occurring every year (Cleusa P Ferri et al., 2005, Wimo A et al., 2003, 
Brookmeyer R et al., 2007). Among developed nations, approximately 1 in 10 older 
people (over 65 years) is affected by some degree of dementia, whereas more than one 
third of very old people (over 85 years) may have dementia-related symptoms and signs 
(Von Strauss E et al., 1999; Corrada MM et al., 2008).  
1.1.6.2 Incidence of Alzheimer’s disease  
The pooled incidence rate of AD among people over 65 years of age in Europe 
was 19.4 per 1000 person-years (Fratiglioni L et al., 2000). The pooled data from two 
large-scale community-based studies of people aged over 65 years in the US Seattle and 
Baltimore areas yielded an incidence rate for AD of 15.0 (male, 13.0; female, 16.9) per 
1000 person-years (Kawas C et al., 2000; Kukull WA et al., 2002). The incidence rate of 
AD increases almost exponentially with increasing age until 85 years of age (Fratiglioni 
L et al., 2000; Kukull WA et al., 2002; Jorm AF et al., 1998; The Canadian Study of 
Health and Aging Working Group. 2000). Studies have confirmed that AD incidence in 
developing countries is generally lower than in North America and Europe. For 
example, the incidence rate of AD among people aged over 65 years was 7.7 per 1000 
person-years in Brazil and 3.2 per 1000 person-years in India (Kalaria RN et al., 2008; 
Chandra V et al., 2001). 
1.1.7 Impact of Alzheimer’s disease at individual and societal levels 
At the individual level, AD is one of the principal causes of physical disability, 
institutionalization, and decreased quality of life. It is estimated that among individuals 
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over 60 years of age dementia contributes 11.2% of the years lived with disability, 
compared with 9.5% for stroke, 8.9% for musculoskeletal disorders, and 5.0% for 
cardiovascular disease (Mathers C et al., 2000). Moreover, AD is associated with a two 
to five fold increased risk of death (Helzner EP et al., 2008; Mehta KM et al., 2008). 
The recent study indicated that in 2006 the world wide total number of patients with 
AD was 26.6 million, and by 2050 the number will quadruple (Brookmeyer R et al., 
2007). It was estimated that about 43% of AD patients require a high level of care such 
as nursing home and institutions. The worldwide overall societal costs of dementia were 
estimated to be more than US$315 billion in 2005, including one third for informal 
care; (Wimo A et al., 2007). Approximately three fourths of the global costs for 
dementia occurred in middle income countries where about 46% of dementia patients 
reside (Kalaria RN et al., 2008). Thus, AD will place heavy economic burden on the 
family and society due to the needs of persistent care and therapy. 
1.2  Etiopathologies of Alzheimer’s disease:  
A considerable research had been undergoing over the past two decades to 
discover the cause of Alzheimer's disease with the ultimate hope of developing safe and 
effective pharmacological treatments. There are several competing hypotheses trying to 
explain the cause of the disease. 
1.2.1 Cholinergic hypothesis 
In the late 1960s and early 1970s, the biochemical investigation of the brains 
of AD patients began with the hope to detect neurochemical abnormality and to provide 
the basis for the development of rational therapeutic interventions analogous to 
levodopa treatment of Parkinson’s disease. Outcome of the research came in the 
mid-1970s with reports of substantial neocortical deficits in the enzyme, choline 
acetyltransferase (ChAT), responsible for the synthesis of acetylcholine (ACh) (Bowen 
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DM et al., 1976; Davies P et al., 1976; Perry EK et al., 1977). Successive findings of 
reduced choline uptake (Rylett RJ et al., 1983), ACh release (Nilsson L et al., 1986) and 
loss of cholinergic perikarya from the nucleus basalis of Meynert (Whitehouse PJ et al., 
1982) confirmed a substantial presynaptic cholinergic deficit in AD. These studies, 
together with the emerging role of ACh in learning and memory (Drachman DA et al. 
1974), led to the “cholinergic hypothesis of Alzheimers disease” [Figure 1(a) and 1(b)] 
(Francis PT et al., 1999). Thus it was proposed that degeneration of cholinergic neurons 
in the basal forebrain and the associated loss of the cholinergic neurotransmission in the 
cerebral cortex and other areas contributed significantly to the deterioration in cognitive 









Figure 1(a): Propose neurochemical changes in Alzheimer's disease (Francis PT et al., 
1999). Key to figure 1(a): 1. reduced cortical cholinergic innervation; 2. reduced 
corticocortical glutamatergic neurotransmission due to neuron or synapse loss; 3. 
reduced coupling of muscarinic M1 receptors to second messenger system; 4. shift of 
tau to the hyperphosphoryalted state—precursor of neurofibrillary tangles; 5. reduced 
secretion of soluble APP; 6. increased production of β-amyloid protein; 7. decreased 
glutamate production.  
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It is hypothesized that these changes give rise to the clinical symptoms of 
Alzheimer’s disease and contribute to the spread of pathology (Francis PT et al., 1993; 
Nitsch RM. 1996; Palmer AM et al., 1990).  
The cholinergic hypothesis of Alzheimer’s disease is based on the presynaptic 
deficits found in the brains of patients with Alzheimer’s disease and studies of the role 











Figure 1(b): Rectification of neurotransmission with cholinesterase inhibitors (Francis 
PT et al., 1999). Key to figure 1(b): 1. AChE inhibitors reduce the breakdown of 
endogenously released ACh, resulting in greater activation of postsynaptic ACh 
receptors; hypothesized consequences: 2. reduced phosphorylation of tau; 3. secretion 
of sAPP returned towards normal; 4. reduced β-amyloid production; 5. glutamatergic 
neurotransmission returns towards normal, possibly due to activation of muscarinic 
and nicotinic receptors.  
The treatment for AD has mainly been focused in the cholinergic hypothesis 
(Paul T Francis et al., 1999). It includes: 
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1.2.1.1 Acetylcholinesterase inhibitors:  
The enhancement of the central cholinergic function has been regarded as one 
of the most promising approaches for the treatment of AD by means of AChE inhibitors. 
Tacrine, which is an acridine derivatives, was found to be a potent acetyl cholinesterase 
inhibitor. It is an orally active amine and readily enters CNS and increases the release 
of ACh from cholinergic nerve endings. It is useful in improving memory performance 
in AD patients. Unfortunately, Tacrine has shown side effects such as hepatotoxicity, 
abdominal cramps, nausea, and vomiting. Physostigmine, has shown some efficacy in 
improving cognitive function in Alzheimer’s disease (Arockia BM et al., 2005). Heptyl 
physostigmine, a more lipophilic analogue is reported to be less toxic than 
physostigmine while retaining its in vitro AChE inhibiting potency. Donepzil and 
rivastigmine have been marked recently for the treatment of the cognitive symptoms of 
AD (Chen YL et al., 1992; Brayson HM et al., 1997). 
1.2.1.2  Acetylcholine release modulators:  
Acetylcholine release modulator, linopiridine enhances the potassium evoked 
ACh release from rat cortex, hippocampus and caudate nucleus in vitro (Fulton B et al., 
1996). Another mechanism of the stimulation of the ACh is via antagonists H3 
histamine receptors (H3-HRS). Two drugs namely Clobenpropit (H3-HR antagonist) 
and thioperamide (H3-HR agonist) have been reported for the treatment of AD (Schnee 
ME et al., 1998; Stark H et al., 19969). Stimulation of ACh release via the increase of 
the presynaptic uptake of endogenous choline, found due to the AChE catalyzed 
enzymatic degradation of ACh, is considered to be an alternative to the receptor 
regulated ACh release (Miyazaki S et al., 1997). 
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1.2.2  Tau hypothesis and neurofibrillary tangles  
Neurofibrillary tangles (NFTs) are an additional neuropathological hallmark of 
AD. These are particularly found in cell bodies, apical dendrites as NFT, in distal 
dendrites as neuropil threads and in the abnormal neurites that are associated with some 
neuritic plaques. The main components of these neuritic plaques are abnormal filaments 
such as straight filaments (SFs) or paired helical filaments (PHFs). The basic 
component of these filaments is the microtubule-associated protein tau (Akaike A. et al., 
1998) which is widely expressed in the mammalian nervous system. Tau, a normal 
axonal protein which binds to microtubules through its microtubulebinding domains 
thus promotes microtubule assembly and stability. Six tau isoforms are produced in the 
adult human brain and are found in neurofibrillary lesions of AD patients (M. Goedert 
et al, 1988). Tau phosphorylation is controlled by the delicate balance between multiple 
kinases (eg, GSK- 3β and CDK5) and phosphatases (eg, PP-1 and PP-2A) (Goedert M 
et al., 1992). Tau hyperphosphorylation in AD begins intracellularly and leads to 
sequestration of normal tau and other microtubule associated proteins. 
Hyperphosphoryalted tau becomes prone to the aggregation into insoluble PHFs and 
larger aggregates in tangles. Both the loss of microtubule stabilization and the tangle 
formation compromise neuronal and synaptic function (Blennow K et al., 2006) (Figure 
2). Tau in tangles becomes ubiquitinated for non-lysosomal degradation, but this 
process is inefficient, and tangles may finally choke affected neurons to death (Goedert 
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1.2.3 Amyloid Cascade Hypothesis 
It is the most preferred model used to explain the pathogenic events causing 
AD. According to this hypothesis, the central event in the disease pathogenesis is an 
imbalance between Aβ production and clearance, with increased Aβ production in 
familial disease and decreased Aβ clearance in sporadic disease. Aβ oligomers could 
directly inhibit hippocampal long-term potentiation and impair synaptic function, in 
addition to the inflammatory and oxidative stress caused by aggregated and deposited 
Aβ. These processes impair neuronal and synaptic function with resulting 
neurotransmitter deficits and cognitive symptoms (K. Blennow et al., 2006) (Figure 3). 
The hypothesis is supported by several evidences and observations (Hardy J et al., 
2002). 
1.  Persons with the Dawn syndrome have an additional copy of the APP gene and    
thus produce more Aβ. 
2 Mutations causing hereditary AD in the APP or PS genes increase the production 
of the longer and more amyloidogenic Aβ42 form of the Aβ peptide. 
3 The Aβ is neurotoxic to several cell lines. 
4 Transgenic mice that are knocked out for β-secretase show rescue of memory 
impairments found in the parental strain with an intactβ-secretase gene. This 
indicates that the overexpression of APP does not cause memory deficits and that 
the production of Aβand or APP C-terminal fragments are required for the 
demonstration of reduced memory function in the mice (Ohno M et al., 2004). 
5 The levels of the deposited Aβ associated with cognitive decline and severity of 
the disease in AD patients and in transgenic animals (Näslund J et al., 2000). 
  
 





















Figure 3: Schematic representation of amyloid cascade hypothesis.
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2.1   Cholinergic neurotransmission and it’s components: 
Cholinergic neurotransmission 
requires the synthesis of 
acetylcholine in the cytoplasm, 
accumulation of acetylcholine in 
synaptic vesicles, and release of 
acetylcholine from the terminal of 
the cholinergic neuron. ACh is 
synthesized from choline and 
acetyl coenzyme A (AcCoA) by the 
enzyme choline acetyltransferase 
(ChAT). Choline gains access to 
the nerve terminal by active 
transport from the extracellular fluid via the high-affinity choline transporter (HAChT). 
AcCoA is synthesized in mitochondria from pyruvate (Pyr) by the enzyme pyruvate 
dehydrogenase (PDH). AcCoA is transported out of the mitochondria for the synthesis 
of ACh. ACh is transported into synaptic vesicles by a vesicular ACh transporter. The 
arrival of an action potential at the nerve terminal causes the synaptic vesicles to fuse 
with the nerve membrane, followed by the exocytotic release of ACh. Upon release, 
ACh can activate postjunctional muscarinic (M) or nicotinic (N) receptors as well as 
presynaptic muscarinic receptors (M); stimulation of the latter inhibits the release of 
ACh. The actions of ACh are rapidly terminated by acetylcholinesterase (AChE), which 
hydrolyzes ACh into choline and acetate. The choline can be transported back into the 
nerve terminal for the synthesis of new Acetylcholine (ACh).
Figure 4: Schematic representation of 
cholinergic neurotransmission 
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According to the cholinergic hypothesis, extensive loss of cholinergic neurons 
found in brains of AD patients postulates a connection between of the cognitive 
impairments of this disorder-especially the loss of memory and a disturbance in 
cholinergic neurotransmission. There are some components which are involved in the 
regulation of presynaptic cholinergic neurotransmission (Table 1) (Sarter M et al., 
2005).  
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Choline acetyltransferase (ChAT), vesicular acetyl choline transporter 
(VAChT), and high-affinity choline transporter (HAChT) are considered as the three 
most important specific markers for cholinergic neurons (Hoover DB et al., 2004). 
2.1.1 Choline acetyltransferase (ChAT) 
Choline acetyltransferase (CHAT), responsible for the synthesis of 
acetylcholine, is presently the most specific indicator for monitoring the functional state 




Figure 5: Synthesis of Acetyl choline (Ach) 
It is a single-strand globular protein, synthesized in the perikaryon of 
cholinergic neurons and transported by both slow and rapid axoplasmic flows to the 
nerve terminals. In cholinergic nerve terminals, ChAT exists in (a) soluble, and (b) 
non-ionically membrane-bound forms. Multiple mRNA species of ChAT (R-, N-and 
M-types) are produced by different splicing in the mouse, rat, and human and 
transcribed from different promoter regions. All transcripts encode the same ChAT 
protein in rodents, while in case of human M-type mRNA has the capability to generate 
both the large and small forms of ChAT proteins and R-and N-types ChAT mRNA 
generate a small form, which corresponds to the rodent ChAT (Oda Y., 1999). The 
genomic structure of ChAT is unique compared to the other enzymes for 
neurotransmitters. The first intron of the ChAT gene includes the open reading frame 
encoding another protein VAChT, which mediates the storage of the newly synthesized 
acetylcholine from the cytoplasm into the synaptic vesicles. The expression of ChAT 
and VAChT appear to be regulated by the several regulatory elements in cholinergic 
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neurons. Immunohistochemical and in situ hybridization studies have revealed that in 
the central nervous system, the medial septal nucleus, the nucleus of the diagonal band 
of Broca, the basal nucleus of Meynert, the caudate nucleus, the laterodorsal tegmental 
nucleus, the medial habenular nucleus, the parabigeminal nucleus, some cranial nerve 
nuclei, and the anterior horn of the spinal cord, are the regions of localization of 
cholinergic neurons. The complicated cholinergic network, constructed by the fibers 
projection of focally distributed cholinergic neurons to many areas in the central 
nervous system, play an important role in neuropsychic activities, such as learning, 
memory, sleep and movement (Oda Y., 1999). Dysfunction of the central cholinergic 
neurons are involved in several neurodegenerative diseases such as Alzheimer’s disease 
and amyotrophic lateral sclerosis, in which disturbance of the central cholinergic 
system does not appear to be closely related to the etiology, but rather to the 
development of clinical symptoms. In addition, recently abnormalities of ChAT have 
been demonstrated in the case of schizophrenia and sudden infant death syndrome (Oda 
Y., 1999).          
2.1.2   High affinity choline uptake transporter (HAChT)  
The high-affinity choline uptake system located in peripheral and central 
cholinergic nerve terminals plays a regulating and rate-limiting role in the intraneuronal 
synthesis of acetylcholine (ACh) (Smart LA et al., 1983; Gilissen C et al., 2003). 
Choline is transferred into the cell by the high-affinity choline transporter where it 
reacts with acetyl CoA in the presence of the enzyme choline acetyltransferase (ChAT) 
to form acetylcholine. Brain synaptosome studies demonstrate two carrier-mediated 
transport systems for choline uptake (Haga T et al., 1971; Yamamura HI et al., 1972; 
Haga T et al., 1973; Kuhar MJ et al., 1978; Kuhar MJ et al., 1973). At high 
concentrations, choline transported primarily by a low-affinity and Na+-independent 
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system that at is inhibited by hemicholinium-3 (HC-3) (Happe HK et al., 1993) with a 
high Ki of approximately 50 μM. This system thought to be ubiquitously present in cells 
and to be required for phosphatidylcholine synthesis. At low concentrations choline is 
transported by a high-affinity, Na+-dependent system that is inhibited by HC-3 with a 
low Ki of 10–100 nM. The high-affinity system is supposed to be present specifically in 
cholinergic neurons, because a substantial proportion of choline is converted to 
acetylcholine only when taken up through the high-affinity system (Haga T et al., 1971; 
Haga T et al., 1973; Kuhar MJ et al., 1978). The proposal that the high-affinity choline 
transport system is unique to cholinergic neurons is supported by the selective loss of 
the high-affinity choline uptake following depletion of cholinergic terminals in a variety 
of denervation studies (Kuhar MJ et al., 1978; Kuhar MJ et al., 1973). Choline uptake is 
generally believed to be the rate-limiting step in acetylcholine synthesis (Haga T et al., 
1971; Yamamura HI et al., 1972; Haga T et al., 1973; Kuhar MJ et al., 1978; Kuhar MJ 
et al., 1973; Tucek R. 1985). In addition, the high-affinity choline uptake is regulated 
by neuronal activity (Simon JR et al., 1975; Murrin LC et al., 1976), suggesting that 
neuronal activity also regulates acetylcholine synthesis. In Alzheimer’s disease, 
cholinergic neurons selectively degenerate. Consistent with the above hypothesis, the 
high-affinity choline transporter is reduced in Alzheimer’s disease (Pascual J et al., 
1991). 
2.1.3 Vesicular acetylcholine transporter (VAChT) 
In cholinergic neurotransmission, acetylcholine (ACh) is the primary signaling 
molecule of cholinergic neurons. The transportation of newly synthesized ACh from the 
cytosol to the cholinergic synaptic vesicles is mediated by VAChT (Arvidsson U et al., 
1997; Bravo DT et al., 2004; Usdin TB et al., 1995). It was reported that, in both the 
peripheral and central nervous systems, there is a strong relationship between the levels 
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of VAChT expression and ACh release (Prado VF et al., 2006). A marked diminution of 
VAChT expression was necessary to interrupt neurotransmission at the neuromuscular 
junction. Even a modest deficiency of VAChT is sufﬁcient to interfere with release of 
ACh in the brain and to affect cognitive behavior in object and social recognition and 
memory function (Prado VF et al., 2006). In the rat brain, staining for both VAChT 
protein & mRNA and ChAT protein & mRNA have explicitly revealed that the VAChT 
is localized in synaptic vesicles within cholinergic terminals (Gilmor ML et al., 1996; 
Ichikawa T et al., 1997; Schafer MK et al., 1995; Schafer MK et al., 1994; Weihe E et 
al., 1996). With the in situ hybridization histochemistry (ISHH) and 
immunohistochemistry (IHC), it was revealed that VAChT-rich presynaptic cholinergic 
nerve terminals are widely distributed in various brain regions, including the cerebral 
cortex, striatum, diagonal band, hippocampus, thalamus, amygdaloidal nucleus, 
cerebellum, and nuclei of cranial nerves. VAChT is now decisively recognized as a 
reliable cholinergic marker, and the development of radiolabeled VAChT imaging probe 
might be a tool for the early detection of AD by using Positron Emission Tomography 
(PET) or Single Photon Emission Computed Tomography (SPECT). 
From the above discussions, it can be concluded that both the HAChT and 
VAChT can be considered as reliable biomarker for studying the cholinergic function in 
AD brain. Radioligands which bind specifically to the HAChT or VAChT, are assumed 
to be used as a neuroimaging probe to investigate the cholinergic neurodegenerative 
process using PET or SPECT. 
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3.1 Research on HAChT imaging probes:  
High affinity choline uptake transporter can be served as a useful marker of the 
functional status of the cholinergic presynaptic terminals and associated with a variety 
of diseases, such as Parkinson’s disease, Alzheimer’s disease, coronary heart diseases, 
tumor cancers (Hara T et al., 2006; Mulholland GK et al., 1998; Gao M et al., 2007). 
Thus, choline transporter systems provide attractive targets for the development of PET 
biomarkers to probe brain, heart, and cancer diseases. HC-3 is a gold standard for 
studying the high-affinity choline transport in vitro (Gilissen C et al., 2003). Carbon-11 
and fluorine-18 labeled HC-3 analogues, [11C]hemicholinium-3 ([11C]HC-3) and 
[18F]hemicholinium-3 ([18F]HC-3), may serve as in vivo PET agents for the choline 
transporter (Zheng QH et al., 2007). Several 11C & 18F labeled derivatives of 
hemicholinium-3, such as [11C] pipzA-4 (Gilissen C et al., 2003) & [18F]FA-4 (Gilissen 
C et al., 2003) were also synthesized and evaluated for the visualization of HACU 




































   Figure 6: Structure of Hemicholinium-3 and its analogues as PET HAChT imaging 
probe 
3.2  Research on VAChT imaging probe:  
Vesamicol [2-(4-phenylpiperinyl) cyclohexanol] (Figure 7) binds with the 
vesamicol binding site on VAChT protein with moderate affinity which lead to 
blockade of vesicular ACh storage and subsequent inhibition of release of this 
neurotransmitter (Parsons S M et al., 1993; Prior C et al., 1992). Thus, (-)-[3H] 
vesamicol acts as an indirect antagonist of cholinergic transmission (Altar CA et al., 
1988). However, additional moderate to high affinity for sigma (σ) receptors (Efange 
SM et al., 1994) and it’s marginal selectivity for VAChT versus σ1 & σ2 receptors, 
makes vesamicol less useful as a selective radiotracer for VAChT imaging. Therefore, 
numerous efforts have been undertaken to improve the selectivity of vesamicol through 
structural modifications. Examples include vesamicol e.g. (–)-[125I]oIV (Shiba K et al., 
2002; Shiba K et al., 2003), (–)-[11C]OMV (Shiba K et al., 2006; Kawamura K et al., 
2006), benzovesamicol e.g. [18F]NEFA (Rogers GA et al., 1994), [18F] FEOBV 
(DeGrado TR et al., 1994; Mulholland G K et al., 1998) or [125I]IBVM (Jung YW et al., 
1990; Sorger D et al., 2000) and trozamicol e.g. [18F]FBT (Mach RH et al., 1997; 
Efange SM et al., 1994; Gage HD et al., 2000; Voytko ML et al., 2001)  [123/125I]MIBT 
(Efange SM et al., 1993; Staley JK et al., 1997) (Figure 7). 
Only [123I] IBVM and [18F] NEFA were used for human studies (Kuhl DE et al., 
1994; Widen L et al., 1993) and rest of them were described as potential radiotracers 
because of their in vivo evaluation in rats, rodents or nonhuman primates. But none of 
these ligands is really accepted for clinical application due to undesired side effects. For 
Chapter III: Previous research on HAChT and VAChT imaging probes 
21 
instance, (+)-[18F] FBT resulted excessively high nonspecific binding in human subjects 
due to its relatively higher affinity for σ receptors (Zhude T et al., 2009) and in the 
human temporal cortex post-mortem, in vitro [123/125I] MIBT binding was reduced by 
45% relative to age-matched controls. [18F]FEOBV invariably exhibits highest binding 
within the striatum and relatively lower accumulation in the VAChT – rich cerebral 
cortex (Giboureau N et al., 2007; Parent M et al., 2012). Currently, (−)-5-[123I]- 
iodobenzovesamicol ([123I]IBVM) is the only radiotracer used for imaging VAChT 
levels in living human brain using single-photon emission computed tomography 
(SPECT). But a significant decrease in [123I]IBVM binding (47−62%) in cingulate 
cortex and parahippocampal amygdaloid in AD subjects compared to control patients 
has been observed (Barret O et al., 2008). However, the slow binding kinetics of 
[123I]IBVM requires scanning for approximately 6 h post-injection, which can be 
stressful for patients (Junfeng Li et al., 2013). Positron emission tomography (PET) 
imaging will be able to carry out scans with higher sensitivity and spatial resolution 
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Zhude Tu and his colleagues have recently reported the synthesis of a new 
class of VAChT ligands (Figure 8) containing a carbonyl group to the 4-position of the 
piperidine ring of vesamicol. In vitro and in vivo evaluation of these compounds have 
revealed that the modification of the vesamicol structure by introducing a carbonyl 
group in between the two rings of the 4-phenylpiperidinyl fragment in the vesamicol 
structure yields benzovesamicol analogues with not only an increased affinity for 
VAChT but also high selectivity for VAChT versus σ receptors (Zhude Tu et al., 2009, 















Figure 8: Analogues of vesamicol as VAChT imaging probe containing a carbonyl 
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Kozaka T et al. in 2014, developed [125I]OIDV (Figure 9), a new 
decalinvesamicol (DV) analogue, as a potent SPECT VAChT imaging probe through in 
vivo biodistribution experiment (Table 2), in vivo blocking experiment (Figure 10), in 







Figure 9: Structure of DV, OIDV and [125IOIDV 
 
Table 2:  Biodistribution in rats after an injection of [125I]OIDV (Kozaka T et., 2014). 
Organs 
Radioactivities  [% ID/g] 
Time post-injection 
10 min 30 min 60 min 120 min 
Blood 0.07 ± 0.02 0.05 ± 0.00 0.04 ± 0.01 0.04 ± 0.00 
Heart 0.69 ± 0.11 0.34 ± 0.05 0.23 ± 0.04 0.13 ± 0.01 
Lung 3.44 ± 1.21 1.82 ± 0.39 0.96 ± 0.13 0.70 ± 0.10 
Liver 2.48 ± 1.48 2.09 ± 0.53 1.97 ± 0.26 1.51 ± 0.16 
Spleen 1.38 ± 0.53 1.47 ± 0.32 1.45 ± 0.45 0.87 ± 0.10 
Pancreas 2.08 ± 0.97 3.00 ± 0.46 3.10 ± 0.85 2.89 ± 0.37 
Stomach 1.18 ± 0.36 0.54 ± 0.08 0.75 ± 0.21 0.40 ± 0.18 
Small intestine 1.01 ± 0.55 1.03 ± 0.21 1.98 ± 0.51 1.86 ± 0.62 
Kidney 2.18 ± 0.92 2.06 ± 0.42 1.57 ± 0.35 1.23 ± 0.09 
Thigh muscle 0.19 ± 0.06 0.17 ± 0.02 0.12 ± 0.01 0.07 ± 0.05 
Cerebral cortex 0.45 ± 0.07 0.42 ± 0.08 0.40 ± 0.06 0.26 ± 0.05 
Striatum 0.44 ± 0.18 0.36 ± 0.07 0.37 ± 0.04 0.25 ± 0.07 
Cerebellum 0.43 ± 0.06 0.36 ± 0.07 0.38 ± 0.05 0.25 ± 0.03 
Rest brain 0.45 ± 0.00 0.37 ± 0.06 0.38 ± 0.07 0.27 ± 0.04 
Values are the mean percent injected dose per gram ± standard deviation. 
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Figure 10: The effect of inhibitors on the uptake of [125I]OIDV. The vertical axis shows 
the mean radioactivity ratio in the brain regions (cerebral cortex, striatum, cerebellum, 
and the remainder) of each group co-injected with (+/-)-vesamicol (0.125 and 0.250 
mmol), (+)-pentazocine (0.125 mmol), and (+)-3-PPP (0.125 mmol), estimating the 
















Figure 11: Ex vivo autoradiography of [125I]OIDV in rat brain at 60 min after 
intravenous injection: (A) control; (B) with (+/-)-vesamicol (0.125 μmol) as an 
inhibitor; (C) with (+)-pentazocine (0.125 μmol) as an inhibitor; and (D) with 
(+)-3-PPP (0.125 μmol) as an inhibitor. Each column of images shows (i) cerebral 
cortex and striatum; (ii) hippocampus; and (iii) cerebellum (Kozaka T et al., 2014).  
 
Despite promising in vitro, ex vivo, and initial in vivo studies, most of the 
radioligand ligands, so far developed, are unsuitable for clinical use due to poor 
selectivity over σ receptors in brain, low extraction from the blood, slow brain kinetics, 
or fast metabolism. The demand to provide higher accuracy in clinical imaging of 
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4.1  Objectives of the Thesis:  
Pathogenesis background of AD is highly complex. Researchers, around the 
glove, have proposed several hypotheses for explaining the mechanism of AD 
development. Among the hypotheses, cholinergic hypothesis has been widely approved 
and the most characteristic abnormality associated with AD is the decline of cholinergic 
neurotransmission. Deficiency in high affinity choline uptake (HACU) and the loss of 
vesicular acetylcholine transporter (VAChT), are two characteristic neurochemical 
changes in AD.  In cholinergic neurons, HACU by the high affinity choline transporter 
(HAChT) is a rate-limiting and regulatory step for the synthesis of Ach and VAChT 
mediates the loading of presynaptic vesicles with newly synthesized acetylcholine. 
Thus, both the HAChT and VAChT appear to be two relatively specific presynaptic 
marker for cholinergic neurons in AD brain. Our research group at the tracer kinetics 
division of Advanced Science Research Center of Kanazawa University has been 
involved for several years in the synthesis and development of vesamicol derivatives as 
VAChT and sigma receptors SPECT/PET imaging probe for the early diagnosis of AD 
(Shiba K et al., 1995, Shiba K et al., 1996, Shiba K et al., 2002, Shiba K et al., 2005, 
Shiba K et al., 2006, Kozaka T et al., 2012, Kozaka T et al., 2014).  
This PhD thesis can be divided into two parts. The objective of PART A 
includes the synthesis and in vitro evaluation of MKC-231, tacirine and its 
corresponding 2-oxo-1-pyrrolidineacetyl derivative as high affinity choline transporter 
imaging agent. The objective of PART B is to develop radiobromine labeled 
Ortho-bromo-trans-decalinvesamicol (OBDV) as a potent and new PET radiotracer for 
VAChT imaging in AD brain through in vivo evaluation and ex vivo autoradiography.  
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PART A 
9-amino-1,2,3,4-tetrahydroacrydine (THA, Tacrine; commercial name: 
Cognix) is well known AchE inhibitors, which produce clinically significant 
improvement in some cognitive deficits observed in AD patients by increasing the 
synaptic availability of Ach by inhibiting the AChE-mediated degradation of ACh to 
choline and acetate. But efficacies of this drug are limited and commonly associated 
with gastrointestinal side effects during long treatment period (Terry A V Jr et al., 
2003). Besides this, there is a deficiency of choline uptake in AD patients. Hence, 
activation of the presynaptic cholinergic function by improving the reduced HACU is 
another better approach for the treatment of AD.  
Although, THA has no effect as HACU enhancer, THA contained 
4-aminopyridine (4- AP) as a partial structure which is already known to increase 
HACU and 1-nitrogen atom of 4-AP also corresponds to the quaternary amine of ACh. 
In 1995, Chaki, H., et al showed acylation of THA lead to the synthesis of novel 
choline uptake enhancers which improve the reduced HACU and some of the structural 
features of N-acyl derivatives of THA resembles acetylcholine. But due to this 
structural modification THA loose its activity as AChE inhibitors (IChaki H., et al., 
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Taking the consideration of this special characteristic feature of N-acyl 
derivatives of THA as HACU enhancer and the role of HAChT to enhance HACU, we 
have synthesized tacirine, the 2,3-dimethylfuran derivative of tacirine (DMTA) and 
their corresponding 2-oxo-1-pyrrolidineacetyl derivatives, namely PTAA and MKC-231 
and evaluated these compounds through in vitro [3H]-Hem-3 binding assay. The 
objectives of the evaluation of these THA derivatives are as follows: 
 To check the affinity of MKC-231, tacirine and the newly synthesized 
THA derivatives (DMTA, PTAA) for HAChT. 
 To find out the possible explanation of mode of action (MOA) of HACU 
enhancer, and 
 To make a possible of clarification of the fact that whether the 
hemicholinium-3 (ChT inhibitor) and HACU enhancer molecules share the 
same binding sites or not. 
 The proposed scheme for the synthesis of THA derivatives: 
1. Synthesis of tacirine (THA) and 2-oxo-1-pyrrolidineacetyl derivative of 
tacirine, namely PTAA.  
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2. Replacement of the phenyl ring on the left part of the tricyclic structure of 
tacirine with a furan ring and synthesis of it’s 2-oxo-1-pyrrolidineacetyl 








Figure 14: Chemical structures of DMTA and MKC-231 
PART B 
In 1989, Rogers et al synthesized eighty-four analogues and derivatives of the 
acetylcholine-storage –blocking drug vesamicol and their potentialities were evaluated 
with the acetylcholine active-transport assay utilizing purified synaptic vesicles from 
Torpedo electric organ (Rogers GA et al., 1989). The evaluation revealed 
that(+/-)-trans-decalinvesamicol possessed the highest affinity for VAChT and it is 6 
times more potent than the (+/-)-cis-decalinvesamicol. On the basis of this observations 
of DV and (–)-oIV (Shiba K et al., 2002, Shiba K et al., 2003), Kozaka T et al. in 2012, 
have synthesized two new decalinvesamicol (DV) analogues, 
o-bromo-trans-decalinvesamicol (OBDV) and o-iodo-trans-decalinvesamicol (OIDV) 















The in vitro binding assay of OIDV and OBDV revealed that the OBDV has 
almost 2.5 times higher affinity than the (+/-)-vesamicol, whereas OIDV was found to 
possess 1.6 times higher affinity than the (+/-)-vesamicol. So, OBDV was found to 
possess higher affinity than OIDV towards VAChT and also higher selectivity over 
sigma receptors. Therefore, there is an opportunity to develop radiolabeled OBDV as a 
new and promising VAChT PET radiotracer.  
A PET tracer provide a useful tool for assessing the severity of cognitive 
dysfunction and monitoring the efficacy of cholinergic therapies for dementia in 
neurodegenerative disorders. However, the large potentiality of these cyclotron 
produced isotopes was not fully explored in clinical nuclear medicine until recently 
because of their short half-lives (t1/2). Oxygen’s two minute half-life means that it needs 
to be pumped directly from a cyclotron to the scan room. Nitrogen’s ten-minute 
half-life and carbon’s twenty-minute half-life are a bit easier to work with, but these 
half-lives mean that there is little time for radiopharmaceutical preparation and delivery 
to the imaging suite. Fluorine-18 with an approximately two-hour half-life allows more 
time for synthesis and for imaging somewhat longer physiologic processes. Even with 
Table 3.  In vitro binding assay of vesamicol analogues (Kozaka T et al., 2012). 
     
Entry Compounds 
Ki (nM) 
VAChT σ-1 σ-2 
1  OIDV 20.5 ± 5.6  241.8 ± 98.9 118.8 ± 57.0 
2  OBDV 13.8 ± 1.2  150.7 ± 62.9 137.5 ± 97.4 
3  DV 13.6 ± 8.8  74.1 ± 39.9 68.3 ± 25.5 
4  vesamicol 33.9 ± 18.1  22.1 ± 3.6 86.7 ± 35.7 
5  DTG - 131.1 ± 39.2 31.7 ± 3.6 
6  pentazocine - 12.1 ± 5.0 1,880.8 ± 953.9 
7  haloperidol - 3.5 ± 0.8 51.6 ± 14.6 
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an on-site cyclotron, these short half-lives limit the biochemical and physiological 
processes that can be imaged.  
Carbon-11, nitrogen-13, and oxygen-15 can only be used to study processes 
that have rapid uptake. For this reason, our research work was aimed to introduce a 
novel VAChT imaging probe, radiolabelled with long-lived positron emitters. Because 
it will allow to radiosynthesize ligand with a good yield and high radiochemical purity 
and to do biodistribution study even after a long period of post-injection. Besides this, 
due to the longer half-life, there is a strong possibility of shipping of the PET 
radiotracer to the research facilities and hospitals for doing research and clinical studies, 
which don’t have any in-house isotope production facility. 
Considering the benefits of using long-lived PET radioisotopes as imaging 
probe for patient diagnosis and research activities and also considering the ortho 
position of –Br substituent in OBDV, the another objective of the PhD thesis is to 
introduce a radiobromine labelled o-bromo-trans-decalinvesamicol (OBDV) as a PET 
radioligand and evaluation of its potentiality as a VAChT imaging probe by various in 
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The evaluation of the potentiality of radiobrominated OBDV as a PET VAChT 
imaging probe was performed the following experiments: 
 Radiolabeling of OBDV with 77Br (t1/2 = 57.0 h), instead of 76Br (t1/2 = 16.0 h) 
because of the longer half-life. Ortho-trimethylstannyl-trans-decalinvesamicol 
(OTDV) was used as a precursor for the radiosynthesis. 
 Determination of partition co-efficient of [77Br]OBDV . 
 In vivo regional biodistribution study of [77Br]OBDV using rats. 
 In vivo metabolic analysis of [77Br]OBDV. 
 In vivo blocking study by using rats to investigate the effect of inhibitors on the 
uptake of [77Br]OBDV. 
 Ex vivo autoradiography of [77Br]OBDV in rat brain. 
4.2 Thesis outline: 
 The PhD thesis consists of seven different chapters.  
Chapter I starts with brief introduction about Alzheimer’s disease, several 
stages of dementia, possible hallmarks of AD, Epidemiology and social impacts of AD 
disease. Etiopathologies of AD on the basis of amyloid cascade hypothesis, Tau 
hypothesis and cholinergic hypothesis are also described in this chapter. 
Chapter II includes the brief explanation of cholinergic neurotransmission.  
This chapter also includes short description of three specific cholinergic markers of 
cholinergic neurotransmission, namely choline acetyltransferase (ChAT), high affinity 
choline transporter (HAChT) and vesicular acetylcholine transporter (VAChT). This 
PhD thesis mainly concentrates on the development and evaluation of HAChT and 
VAChT imaging agent. 
Chapter III of the thesis focuses the continuous research works around the 
world and also research works of the group of Professor Kazuhiro Shiba at Advanced  
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Science Research Center, Kanazawa University for the development of SPECT/PET 
HAChT and VAChT imaging probe for the early diagnosis of AD.  
Chapter IV describes the main objectives of the PhD thesis in continuation 
with the previous investigations and reported results. This chapter also includes the 
brief outline of each chapter of this thesis.   
Chapter V describes the evaluations of MKC-21, tacirine (THA) and it’s 
corresponding 2-oxo-1-pyrrolidineacetyl derivative as the HAChT imaging agent which 
includes the syntheses of tacirine, the 2,3-dimethylfuran derivative of tacirine (DMTA) 
and their corresponding 2-oxo-1-pyrrolidineacetyl derivatives, namely PTAA and 
MKC-231 and the in vitro evaluation of these compounds through [3H]-Hem-3 binding 
assay. A brief discussion on the results of the in vitro binding assay is also incorporated 
in this chapter. 
Chapter VI focuses on the in vivo evaluation of radiobromine labelled OBDV 
as a new and potent PET VAChT imaging probe, which includes the syntheses of 
OBDV & OTDV, radiosynthesis of [77Br]OBDV, and several in vivo studies & ex vivo 
autoradiography of rat’s brain with [77Br]BDV. Detailed discussion on the basis of the 
results of in vivo studies and ex vivo autoradiography is also incorporated in this 
chapter. 
The dissertation ends with the Chapter VII that gives some concluding 
remarks on the findings of in vitro evaluation of THA derivatives as HAChT imaging 
agent and in vivo evaluations of radiobromine labelled decalinvesamicol analogue and 
PET VAChT imaging probe. This chapter also includes some direction for future 
research in the development of SPECT/PET HAChT and VAChT imaging probe for the 
early diagnosis of AD.    
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5.1     Results 
5.1.1  Chemistry: 
The cyclization of 2-Amino benzonitrile (1) and 2-Amino-4, 
5-dimethyl-3-furancarbonitrile (2) with cyclohexanone by means of ZnCl2 in toluene, 








Figure 16: Scheme for the syntheses of tacirine and DMTA. 
The acylation of Tacirine (3) and DMTA (4) with methyl 
2-oxo-1-pyrrolidineacetate furnished PTAA (5) and MKC-231 (6) with the yield of 79% 








Figure 17: Scheme for the syntheses of PTAA and MKC-231.
Chapter V: Evaluation of tacirine derivatives as HAChT imaging probes 
35 
5.1.2 In vitro HAChT [3H]Hemicholinium-3 ([3H]HC-3) binding assay: 
The inhibition activities of tacirine (THA), MKC-231 and the two newly 
synthesized tacirine derivatives, namely DMTA and PTAA were measured by 
displacement of a typical HAChT antagonist [3H]HC-3 (Dissociation constant: Kd = 
19.1 nM) (Quirion R., 1987, 293-303) in rats cerebral membrane. The percent inhibition 
against the binding of [3H]HC-3 to HAChT were calculated using GraphPad Prism v4 
software (Figure 18). HC-3 showed the highest affinity for HAChT (IC50 = 20 nM). 
Tacrine (THA) showed very insignificant inhibition activity (IC50 = 1000 nM). Both the 
2,3-dimethylfuran derivative of tacirine, DMTA and 2-oxo-1-pyrrolidineacetyl 
derivative of tacirine, PTAA showed no affinity for HAChT. MKC-231 also did not 











Figure 18: In vitro HAChT [3H]Hemicholinium-3 binding assay    
 
5.2 Discussions: 
 High affinity choline uptake (HACU) system is located especially in 
presynaptic cholinergic nerve terminals. HACU by the HAChT is found to be a 
regulating and rate limiting step in the synthesis of ACh. Hence, a ligand with a high 
affinity for HAChT would be an ideal marker for the study of the state of cholinergic 
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presynaptic terminals. Hemicholinium-3 is an indirect acetylcholine antagonist, because 
it decreases the synthesis of acetylcholine by inhibiting the reuptake of choline by the 
high-affinity choline transporter (ChT). As HC-3 is a quaternary ammonium salt, it 
cannot cross BBB and radiolabeled quaternary ammonium HC-3 derivatives cannot be 




Figure 19: Chemical structure of Hemicholinium-3 (HC-3) 
MKC-231, 2-(2-Oxo-pyrrolidine-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro 
[2, 3-b]quinolin-4-yl) acetoamide, has been reported to enhance HACU in hippocampal 
synaptosomes in in vitro treatment and ameliorates learning deficits in AF64A-treated 
rats with a single oral administration (Bessho et al., 1996). Although MKC-231 
potentially enhances cholinergic activity at synaptic terminals and improves learning 
impairment observed in AF64A-treated rats and mice, no precise HACU enhancement 
mechanism has been elucidated. 
Acylation of THA, an AchE inhibitor, led to the synthesis of novel choline 
uptake enhancers which improve the reduced HACU and loose its activity as AChE 
inhibitors (IChaki H., et al., 1995; IIChaki H., et al., 1995). 
 In the effort of developing HAChT imaging probe we have evaluated tacirine, 
the 2,3-dimethylfuran derivative of tacirine (DMTA) and their corresponding 
2-oxo-1-pyrrolidineacetyl derivatives, namely PTAA and MKC-231 through in vitro 
[3H]Hemicholinium-3 ([3H]HC-3) binding assay to investigate their affinity for HAChT. 
From the the in vitro binding assay, it was revealed that only hemicholinium-3 
expressed high affinity for HAChT (IC50 = 20 nM). Tacrine (THA) showed some 
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degree of inhibition activity (IC50 = 1000 nM), but it is very insignificant compared to 
the inhibition activity of hemicholinium - 3 (IC50 = 20 nM). Both the 2,3-dimethylfuran 
derivative of tacirine, DMTA and 2-oxo-1-pyrrolidineacetyl derivative of tacirine, 
PTAA showed no affinity for HAChT. Although, MKC-231, is known to enhance 
HACU and increase the synthesis and release of ACh in in vitro and in vivo studies 
(Takashina K et al. 2008), it did not show any affinity for the HAChT in 
[3H]Hemicholinium-3 binding assay. Other inhibitors like choline chloride (ChCl), 
Acetylcholine chloride (AChCl), Carbamylcholine Chloride (CaChCl) showed no 
binding affinity for high affinities choline transporter (ChT). 
As no inhibitors (except Hem-3), MKC-231, THA and the synthesized THA 
derivatives did not exhibit any inhibition towards HAChT, so it is worthy to search for 
the new molecules having high affinity for choline transporter (HAChT) for the 
extensive study of HACU.  
5.3    Experimental: 
5.3.1 Syntheses: 
5.3.1.1 Synthesis of 1,2,3,4-Tetrahydro-acridin-9-yl amine (THA) (3)  
To a mixture of 2-Aminobenzonitrile (1) (2 g; 16.93 mmol) and cyclohexanone 
(14 mL; 135.44 mmol) in toluene (60 mL) placed in a round bottom flask connected to 
a Dean-Stark water separator, ZnCl2 (6.93 g; 50.79 mmol) was added. The mixture was 
refluxed for 06 hours. After that, the reaction mixture was cooled at room temperature 
and the remaining solids were treated with NaOH (2M, 70 mL). This mixture was then 
again refluxed for about another 06 hours with stirring. On cooling to room temperature, 
the reaction mixture were extracted with CHCl3. The organic layers were combined, 
dried over anhydrous MgSO4 and concentrated to dryness under reduced pressure. 
Purification of the residue by column chromatography on silica-gel by using ethyl 
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acetate with trace ET3N afforded the target compound (3) (3.10 g, 92.26 %) as a yellow 
solid; 1H NMR δ 7.90-7.87 (d, 1H), 7.70-7.67 (d, 1H), 7.58-7.54 (t, 1H), 7.38-7.34 (t, 
1H), 4.63 (s, 2H), 3.05-3.01 (t, 2H), 2.64-2.60 (t, 2H), 1.98-1.90 (m, 4H); 13C NMR δ 
158.60, 146.58, 146.24, 128.92, 128.40, 123.85, 119.50, 117.13, 110.44, 34.14, 
23.75,22.86, 22.78. EI MS m/z 199 (M+, 86.2). 
5.3.1.2  Synthesis of 2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-amine 
(DMTA)(4): 
To a mixture of 2-Amino-4,5-dimethyl-3-furancarbonitrile (2) (2.00 g; 14.69 
mmol) and cyclohexanone (12 mL; 117 mmol) in toluene (60 mL) placed in a round 
bottom flask connected to a Dean-Stark water separator, ZnCl2 (6 g; 44.00 mmol) was 
added. The mixture was refluxed for 06 hours. After that, the reaction mixture was 
cooled at room temperature and the remaining solids were treated with NaOH (2M, 70 
mL). This mixture was then again refluxed for about another 06 hours with stirring. On 
cooling to room temperature, the reaction mixture were extracted with CHCl3. The 
organic layers were combined, dried over anhydrous MgSO4 and concentrated to 
dryness under reduced pressure. Purification of the residue by column chromatography 
on silica-gel by using hexane: ethyl acetate (1:1) with trace ET3N afforded the target 
compound (4) (1.37 g, 43.08 %) as a yellow solid; 1H NMR δ 4.35-4.30 (s, 2H), 
2.89-2.85 (t, 2H), 2.47-2.45 (t, 2H), 2.30 (s, 6H), 1.91-1.81 (m, 4H); 13C NMR δ 160.42, 
151.34, 146.10, 145.67, 110.24, 107.28, 105.22, 33.04, 29.00, 22.94, 22.89, 11.28, 
10.27. EI MS m/z 217 (M+, 86.9). 
5.3.1.3 Synthesis of 2-(2-Oxo-pyrrolidin-1-yl)-N-(1,2,3,4-tetrahydro-acridin-9-yl)- 
acetamide (PTAA) (5). 
To a mixture of 1,2,3,4-tetrahydro-acridin-9-yl amine (3) (1 g; 5.04 mmol) and 
DMF (50.4 mL), NaH (4.032 g; 100.08 mmol) was added at room temperature 
maintaining Argon environment. After 01 hour of stirring, methyl 
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2-oxo-1-pyrolidineacetate (2.03 mL; 15.12 mmol) was added to the reaction mixture 
maintaining the argon environment at room temperature. The reaction was kept in 
stirring for another one hour at room temperature. After a total of 2 hour, the reaction 
mixture were extracted with ethyl acetate. The organic layers were combined, dried 
over anhydrous MgSO4 and concentrated to dryness under reduced pressure. 
Purification of the residue by column chromatography on silica-gel by using ethyl 
acetate: ethanol (50:1) with trace ET3N afforded the target compound (5) (1.3 g, 
79.75 %); 1H NMR δ 8.57-8.56 (s, 1H), 7.99-7.96 (d, 1H), 7.76-7.72 (d, 1H), 7.64-7.59 
(t, 1H), 7.48-7.43 (t, 1H), 4.22 (s, 2H), 3.68-3.63 8 (t, 2H), 3.15-3.10 (t, 2H), 2.80-2.75 
8t, 2H), 2.50-2.44 (t, 2h), 2.17-2.10 (m, 2H), 1.98-1.93 (m, 2H), 1.88-1.82 (m, 2H); 13C 
NMR δ 176.76, 166.99, 159.85, 146.90, 137.75, 128.83, 127.22, 126.06, 123.55, 
121.95,49.01, 48.24, 33.99, 30.38, 25.54, 22.67, 22.45, 18.25. EI MS m/z 324 (M+, 
78.6).  
5.3.1.4  Synthesis of 2-(2-Oxo-pyrrolidine-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydro 
furo [2, 3-b] quinolin-4-yl) acetoamide (MKC-231) (6). 
To a mixture of 2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-amine 
(0.338 g; 1.56 mmol) (4) and DMF (15.6 mL), NaH (1. 248 g; 31.2 mmol) was added at 
room temperature maintaining Argon environment. After 01 hour of stirring methyl 
2-oxo-1-pyrolidineacetate (0.63 mL; 4.63 mmol) was added to the reaction mixture 
maintaining the argon environment at room temperature. The reaction was kept in 
stirring for another one hour at room temperature. After a total of 2 hour, the reaction 
mixture were extracted with ethyl acetate. The organic layers were combined, dried 
over anhydrous MgSO4 and concentrated to dryness under reduced pressure. 
Purification of the residue by column chromatography on silica-gel by using ethyl 
acetate with trace ET3N afforded the target compound (6) (0.350 g, 65%); 
1H NMR δ 
8.45 (s, 1H), 4.14 (s, 2H), 3.64-3.59 (t, 2H), 2.96-2.91(t, 2H), 2.64-2,59 (t, 2H), 2.47-43 
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8t, 2H), 2.32-2.09 (m, 8H), 1.88-1.76 (m, 4H); 13C NMR δ 176.48, 167.67, 159.95, 
151.65, 150.14, 134.91, 123.50, 116.37, 108.19, 48.84, 47.71, 32.74, 30.29, 24.25, 
22.69, 22.60, 18.12, 11.58, 8.92. EI MS m/z 342 (M+, 81.4).  
5.3.2 Preparation of homogenate from rat’s cerebral tissues: 
Animal experiments were performed in compliance with the Guidelines for the 
Care and Use of Laboratory Animals at the Takara-machi Campus of Kanazawa 
University. Brain Homogenate of rats were prepared with the slight modification of 
previously described protocol of Sandberg K et al (Sandberg et al., 1985). 
Sprague-Dawley rats (8 weeks, male, 250–300 g) cerebrum or livers were homogenized 
in ice-cold 0.32 M sucrose with a Teflon-glass homogenizer. The homogenate was 
centrifuged at 1000g at 4 oC for 10 min. The resulting precipitate was removed and the 
supernatant was centrifuged at 20,000 g at 4 oC for 20 min. This crude mitochondrial 
pellet was resuspended in 20 vols. of ice-cold distilled water and dispersed with the 
Teflon homogenizer with 1000 rpm and the homogenate centrifuged at 8000 g run for 
20 min. The supernatant and buffy coat were collected and pelleted at 48,000 g for 20 
min. The pellet was washed 4 times in 20 vols. of 50 mM Glycylglycine buffer (pH 7.8) 
containing 200 mM NaCl by resuspending via Teflon homogenizer. Then the 
homogenate was centrifuged at 55,000 g for about 15 min and the resulting pellet was 
again resuspended in 50 mM Glycylglycine buffer (pH 7.8) containing 200 mM NaCl 

















The Homogenate was centrifuged with a rotation of 1000 × g for 10 mins at 40C. After 
this centrifugation, a suspension of brain tissue in 0.32M Sucrose aq. was formed. 
 
 


























Figure 20: Flow chart for the homogenate reparation of rat cerebral tissues. 
 
Nucleus pellets (P1) 
 
 
Supernatant solution (S1) 
 
 
Supernatant fraction was centrifuged with 20,000 × g for about 20 mins at 4oC 
Crude Mitochondrial pellet (P2) 
 
 
a. Addition of aq. 0.32M sucrose solution in the amount of 10 vols. of brain tissue weight. 
b. Mash the brain tissue with a Teflon homogenizer with a rotation of 800-1000 rpm at 4oC 
 
Homogenate (Suspension of brain tissue in aq. 0.32M Sucrose) 
 
 
        
Supernatant solution (S2) 
 
 
a. This crude mitochondrial pellet was resuspndend in 20 vols. of ice-cold distilled water. 
b. Dispersed with a Teflon homogenizer with 1000 rpm, 2-3 strokes. 
c. The homogenate was centrifuged at 8,000 × g for 20 mins. 
a. The supernatant and buffy coat were collected and pelleted at 55,000 × g for 20 mins. 
b. The pellete was washed 4 times with 20 vols. of 50 mM glycylglycine buffer (pH 7.8)  
containing 200 mM NaCl.  
c. Resuspended the pellet with the Teflon homogenizer with 1000 rpm, 2-3 strokes.   
d. The homogenate was centrifuged at 55,000 × g for about 15 mins. 
e. At last the pellet was again resuspunded with 50 mM glycylglycine buffer (pH 7.8)  
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5.3.3 In vitro HAChT [3H]Hemicholinium-3 binding assay: 
[3H]Hemicholinium-3 (Kd = 19.1 nM) (Quirion R 1987) was used as a specific 
radioligand for the HAChT receptor. Rat cerebral membranes were added to each 
ice-cold assay tube containing [3H]HC-3 and the displacing ligands at various 
concentrations (1.0 × 10-9 – 10-4) in 50 mM Glycylglycine buffer (pH 7.8) containing 
200 mM NaCl in quadruplicate. After the addition of tissues in an ice bath, each 
reaction mixture in the tube was incubated at 25oC for 30 min. The incubation was 
terminated by pitting tubes into ice-cold water followed by immediate filtration using a 
cell harvester through glass-microfiber filters (Whatman, GF/B), which were presoaked 
in the in 0.5% (v/v) polyethyleneimine for 01 h to reduce non-specific binding. The 
filters were washed with 50 mM Tris-HCl buffer (pH 7.8), and their radioactivities were 
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6.1    Results 
6.1.1  Chemistry: Synthesis of OBDV and OTDV 
4-(2-bromophenyl) piperidine (7), the key intermediate for the synthesis of 
OBDV, was derived from ortho–bromobenzaldehyde by four-step reactions (Figure 21) 
(Kozaka T et al., 2012). Coupling reaction of 4-(2-bromophenyl) piperidine with 
trans-decalin-2,3-oxide  furnished OBDV (8) in 57% yield. The bromo substituent of 
OBDV was replaced by a trimethylstannyl group with the reaction of Pd(PPh3)4 and 
hexamethylditin to obtain the precursor, o-trimethylstannyl-trans-decalinvesamicol 


















Ref: Kozaka, T. et al. Bioorg Med Chem., 2012, 20, 4936-4941. 
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6.1.2  Radiosynthesis and purification of [77Br]OBDV:  
o-trimethylstannyl-trans-decalinvesamicol (OTDV) was the main precursor for 
the synthesis of [77Br]OBDV. [77Br]OBDV was radiosynthesized by the tin-bromine 
exchange reaction from OTDV with no-carrier added [77Br]Br- (Specific activity: 2.0 
TBq/µmol), HCl and chloramine-T (Figure 22). [77Br]OBDV was obtained with a 
radiochemical yield of 52.3-65.8%. [77Br]OBDV was purified with reversed phase 
HPLC equipped with a Zorbax-ODS RX-C18 column (9.6 mm × 250 mm) at a flow 
rate of 4.0 mL/min with a mobile phase of acetonitrile: H2O: monoethanolamine 
(90:10:0.2, v/v/v) at 40°C and radiochemical purity was found to be greater than 99%. 
Ultraviolet (UV) absorption was monitored at 230 nm. The retention time of 
[77Br]OBDV was found 10 min and the chemical identity of [77Br]OBDV was 
confirmed by co-injection with reference OBDV (retention time: 10 min) on HPLC 
under the same condition [Figure 23 (a) and 23 (b)]. The specific activity of 
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6.1.3  In vivo biodistribution of [77Br]OBDV: 
    The distribution of [77Br]OBDV in the rat brain regions, blood, urine and other 
organs of interest at 2, 30 and 60 minutes post-injection are presented in Table 3. The 
blood-brain barrier was readily penetrated by [77Br]OBDV. The accumulations of 
[77Br]OBDV in the cerebral cortex, striatum, cerebellum and the rest of the rat brain 
regions were 0.64 ± 0.06% ID/g, 0.62 ± 0.08% ID/g, 0.61 ± 0.09% ID/g and 0.61 ± 
0.07% ID/g, respectively, at 2 min post injection. The average accumulations of 
[77Br]OBDV in all brain regions of interest were 0.56 ± 0.06% ID/g and 0.50 ± 0.05% 
ID/g, respectively, at 30 and 60 min post-injection. The clearance of [77Br]OBDV from 
blood was also very rapid and the radioactivity in blood was found to be 0.14 ± 0.01% 
ID/g at 2 min post-injection. At 60 min post-injection, maximum accumulation of 
[77Br]OBDV was observed in the pancreas (2.98 ± 0.33% ID/g) and small intestine 
(1.69 ± 0.26% ID/g). The accumulation of [77Br]OBDV in the lung was also found very 
high (5.57 ± 0.72% ID/g) at 2 min post-injection, but at 60 min post-injection, the 
accumulation was decreased to 1.23 ± 0.14% ID/g. The accumulations of [77Br]OBDV 
in bladder at 2, 30 and 60 min post-injection were found 0.15 ± 0.04 % ID/g, 0.19 ± 
0.04 % ID/g and 0.20 ± 0.03 % ID/g respectively. At 2, 30 and 60 min post-injection, 
the accumulations of [77Br]OBDV in urine were found 0.04 ± 0.04 % ID/g, 0.25 ± 0.02 
ID/g and 0.32 ± 0.24 ID/g respectively. At both the 30 & 60 min post-injection, the 
accumulations of [77Br]OBDV in bladder and urine were found very low, compared to 
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Table 4: Biodistribution of [77Br]OBDV in rats after intravenous injection of the tracera 
 
         Post injection time 
2 min    30 min   60 min 
Blood   0.14 ± 0.01     0.11 ± 0.12  0.04 ± 0.01 
Heart   2.19 ± 0.52  0.39 ± 0.03  0.27 ± 0.03 
Lung   5.57 ± 0.72  1.54 ± 0.24  1.23 ± 0.14 
Pancrease  2.10 ± 0.55  2.52 ± 0.98  2.98 ± 0.33 
Spleen   0.89 ± 0.34  1.35 ± 0.25  1.02 ± 0.23 
Kidney   2.90 ± 0.36  2.18 ± 0.27  1.68 ± 0.52 
Bladder   0.15 ± 0.04  0.19 ± 0.04  0.20 ± 0.03 
Urine   0.04 ± 0.04  0.25 ± 0.02  0.32 ± 0.24 
Small intestine  0.93 ± 0.14  1.24 ± 0.44  1.69 ± 0.26 
Stomach  0.26 ± 0.19  0.32 ± 0.28  0.22 ± 0.14 
Liver   1.04 ± 0.12  1.79 ± 0.05  1.62 ± 0.04 
Cerebral cortex  0.64 ± 0.06  0.52 ± 0.11  0.50 ± 0.05 
Striatum  0.62 ± 0.08  0.59 ± 0.05  0.53 ± 0.09 
Cerebellum  0.61 ± 0.09  0.56 ± 0.04  0.45 ± 0.05 
Others   0.61 ± 0.07  0.58 ± 0.05  0.50 ± 0.05 
aRadioactivities are expressed as % injected dose per gram tissue (% ID/g). The values 
are the mean ± standard deviation (SD) of four rats (n = 4) at each time point. 
6.1.4   In vivo blocking studies 
The ratio of mean radioactivity in cerebral cortex, striatum, cerebellum, and 
the rest of the brain for [77Br]OBDV (Control only) and for the co-injection of 
(+/-)-vesamicol (0.250 µmol) or (+)-pentazocine (0.250 µmol) or (+)-3-PPP (0.250 
µmol) with the [77Br]OBDV was presented in Figure 24. The uptakes of [77Br]OBDV in 
the cerebral cortex, striatum, cerebellum, and the rest of the brain were inhibited with 
the co-administration of 0.250 µmol (+/-)-vesamicol by an amount of 42%, 43%, 42%, 
and 45%, respectively, relative to [77Br]OBDV (Control only). The inhibition effect of 
(+/-)-vesamicol on the uptake of [77Br]OBDV in all the brain regions was also found 
very significant (P < 0.001 to P < 0.01) with the Tukey’s multiple comparison test in 
Tissue 
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conjunction with an ANOVA. However, with the co-administration of 0.250 µmol 
(+)-pentazocine or 0.250 µmol (+)-3-PPP, no significant difference in the accumulation 
of [77Br]OBDV from the control ([77Br]OBDV only) values were observed in all the 

















Figure 24: The effect of inhibitors on the uptake of [77Br]OBDV. The vertical axis 
shows the mean radioactivity rate in the brain regions (cerebral cortex, striatum, 
cerebellum, and the rest) of each group co-injected with (±)-vesamicol (0.250 µmol) or 
(+)-pentazocine (0.250 µmol) or (+)-3-PPP (0.250 µmol), estimating the control 
([77Br]OBDV only) as 100%. The stars (*) in the figure indicate the significant 
difference between the uptake of [77Br]OBDV co-injected with (+/-)-vesamicol (0.250 
µmol) and none as control in all the brain regions. A one-way ANOVA followed by a 
Tukey’s multiple comparison test was performed by GraphPad Prism Version 4 
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6.1.5   In vivo metabolite analysis 
The standard Rf value of [
77Br]OBDV was found to be 0.26 (Figure 25) on 
TLC, where, hexane: ethyl acetate: triethylamine (3:1:0.1, v/v/v) was used as mobile 
phase. A very weak trace spot around the starting point and a strong spot of Rf value 
0.26 ± 0.02 were observed on the TLC plate in case of the brain samples. In case of the 
plasma samples, only an intense spot of highly polar radioactive metabolite around the 











Figure 25: In vivo metabolite analysis of [77Br]OBDV in the rat brain 60 minutes after 
intravenous injection. Here, (A) & (B) indicate TLC analysis of plasma and brain 
samples, respectively, and (C) indicates TLC analysis with the control ([77Br]OBDV). 
6.1.6   Partition coefficient: 
 The partition coefficient (log Po/w) of [
77Br]OBDV was found to be 2.93 ± 0.03, 
which indicates that [77Br]OBDV has a reasonable degree of lipophilicity to penetrate 
the blood–brain barrier (BBB). 
6.1.7 Ex vivo autoradiography: 
 VAChT-rich regions of the rat brain was prominently visualized by the ex vivo 











0.26 ± 0.02 
0.26 
  Chapter VI: Evaluations of radiobromine labeled decalinvesamicol derivative  
50 
regions of rat’s brain [Figure 25 (a)]. The high accumulation of [77Br]OBDV was 
observed in the cerebral cortex, striatum, diagonal band, hippocampus, thalamus and 
amygdaloidal nucleus. The localization of [77Br]OBDV binding was also visualized in 
the molecular and granular cell layers, facial nucleus and trigeminal nucleus in the 
cerebellum. No specific accumulation of the radiotracer was observed in any brain 
regions of rats with the co-injection of 0.250 μmol (+/-)-vesamicol with control 
















Figure 26: Ex vivo autoradiographic distribution of [77Br]OBDV in the rat brain at 30 
min post-injection (A) with the control ([77Br]OBDV only); (B) co-injection of 0.250 
μmol (+/-)-vesamicol with [77Br]OBDV in the rat brain as an inhibitor. Abbreviations: 
AM, anteromedial thalamus; AV, anteroventral thalamus; CBL, cerebellum; CPU, 
striatum; CTX, cerebral cortex; DB, diagonal band; HPC, hippocampus; PLCo, 
posterolateral cortical amygdaloidal nucleus; 5, trigeminal nucleus; 7, facial nucleus. 
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6.2    Discussions: 
In vitro evaluation of OBDV revealed its high affinity and selectivity for 
VAChT (Kozaka T et al., 2012). Hence, it was expected that OBDV, radiolabeled with a 
suitable positron emitter, possesses the strong potentiality to be used as VAChT PET 
ligand. Bromine and iodine is very similar to each other in chemistry and the chemical 
reactivity of bromine is milder than that of fluorine but greater than that of iodine. The 
binding strength of C-Br bond is 59 kcal/mol, while those of C-I and C-F are 45 and 
114 kcal/mol, respectively. So, radiobromine labeled compounds are less vulnerable to 
in vivo dehalogenation than iodinated derivatives. Moreover, the obtainability of 
various radioisotopes of bromine is also an extra benefit of using radiobromine labeled 
neuroimaging probe over radioflourine labeled neuroimaging probe (Maziere B et al., 
1986). On the basis of the features of high affinity for VAChT and selectivity over 
sigma receptors, radiobromine-labeled OBDV was evaluated through in vivo 
evaluations and ex vivo autoradiography as a potential VAChT PET ligand. Among the 
various radioisotopes of bromine, 76Br is the mostly used for clinical investigations. It is 
a relatively long-lived (t1/2 = 16.2 h) positron emitter that decays with both the positron 
emission (54%) and electron capture (IAEA, technical series no. 468). To make the best 
use of the advantage of longer half-life for the present radiosynthesis and in vivo 
evaluation experiments, we have radiolabeled OBDV with 77Br instead of 76Br. 77Br has 
a half-life of 56 h and decays nearly completely (99.3%) by electron capture, with 
promising gamma rays at 0.239 and 0.520 MeV (IAEA, technical series no. 468). 
[77Br]OBDV was radiosynthesized by the oxidative radiobromination of the precursor, 
OTDV (Figure 20), with no-carrier added conditions with the radiochemical yield of 
52.3-65.8% and the specific activity of 322 ~ 406 GBq/µmol. 
Maximum accumulation of [77Br]OBDV (>0.6% ID/g) in the cerebral cortex, 
striatum, cerebellum and the rest of the brain was found at 2 min post-injection from the 
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intracerebral biodistribution pattern of [77Br]OBDV (Table 4). This confirmed the rapid 
penetration of [77Br]OBDV into the brain by crossing the blood–brain barrier (BBB). 
Rapid diffusion through the BBB is also a confirmatory indication of the suitable lipid 
solubility of [77Br]OBDV, so that it can easily be extracted in the brain. 
 At 2-min post-injection, the initial brain uptakes of [77Br]OBDV in striatum, 
cerebral cortex, cerebellum, and the rest of brain were (0.62 ± 0.08% ID/g), (0.64 ± 
0.09% ID/g), (0.61 ± 0.06% ID/g), and (0.61 ± 0.07% ID/g) respectively. This relatively 
homogenous biodistribution in the brain regions is assumed to express the nonspecific 
binding of [77Br]OBDV reflected by cerebral blood flow in the brain. However, at 30 
min post-injection, the specific brain regional accumulation of [77Br]OBDV was 
observed. The highest accumulation of [77Br]OBDV was found in the striatum, which 
matched with the known distribution of VAChT density as the highest level of VAChT 
was found in the striatum (Efange SM et al., 1995; Frey KA et al., 1998; Efange SM et 
al., 2000). Moderate to high accumulation of [77Br]OBDV was also observed in the 
cortex, cerebellum and the other regions of the brain. This findings conclude that 
[77Br]OBDV was accumulated in the VAChT rich regions distributed throughout the 
whole brain, which is in accordance with the regional brain accumulation of [125I]OIDV 
(Kozaka et al., 2014). 
At 2-min post-injection, the initial blood uptake of [77Br]OBDV was found 
very low (0.14 ± 0.01 & ID/g). The clearance of radioactivity from the blood was also 
very fast and the radioactivity in blood was 0.04 ± 0.01% ID/g at 60 min post-injection. 
The low blood uptake and the fast blood wash out are advantageous for brain imaging. 
In vivo biodistribution study of [77Br]OBDV, the average radioactivity in blood at 2, 30 
and 60 min post-injection was found 0.10 ± 0.05 %ID/g. In case of in vivo [77Br]OBDV 
blocking experiments, the radioactivity in blood at 30 min post-injection were found 
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0.05 %ID/g. The radioactivity in blood in both the in vivo biodistribution and in vivo 
[77Br]OBDV blocking experiments was so low that the possibility of confounded 
experimental results due to the residual level of [77Br]OBDV in blood within 
intracerebral blood vessels and/or nonspecifically bound to vascular endothelial cells, 
was considered very minor or negligible.   
Depending on the specific activity of [77Br]OBDV, the injected radioactivity of 
[77Br]OBDV (1.0-1.58 MBq (2.46-3.89 pmol)/ rat) in autoradiographic study was 9-13 
times higher than that (0.111 MBq (270.7 fmol) / rat) in in vivo blocking study. 
However, the regional brain distribution in autoradiogram image accorded with that in 
in vivo distribution study. Thus, the confounding effects of intra-vascular versus 
intra-parenchymal [77Br]OBDV depending on the chemical amount of [77Br]OBDV do 
not have to be considered. 
Significant blocking effects on the regional brain distribution of [77Br]OBDV 
by (+/-)-vesamicol (0.250 µmol) was revealed in the in vivo blocking studies. This 
validates that [77Br]OBDV binds to vesamicol binding site on VAChT with high 
affinity (Figure 24). In contrast, with both the (+)-pentazocine (selective σ-1 receptor 
agonist) or (+)-3-PPP (σ-1 and σ-2 receptor agonist), separately co-injected with 
[77Br]OBDV into the rats, no significant inhibition of the uptake of [77Br]OBDV in any 
brain region was observed. This negligible changes in in vivo brain regional uptake of 
[77Br]OBDV, co-injected with 250 µmol of (+)-pentazocine or (+)-3-PPP, revealed that 
[77Br]OBDV does not significantly bind to σ-1 and σ-2 receptors like most vesamicol 
analogues do, presumably because of the o-Br group of [77Br]OBDV, which prevents 
binding to σ-1 and σ-2 receptors but not VAChT. In in vivo blocking studies, the molar 
quantities (0.250 µmol) of both the (+)-3-PPP and (+)-pentazocine are almost 9 × 105 
times higher than that of injected [77Br]OBDV (273.4 fmol) in each rat and are 
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maximum enough to block the accumulation of [77Br]OBDV in all brain regions. But no 
inhibition of the accumulation of [77Br]OBDV was observed, which also confirm the 
selectivity of [77Br]OBDV binding to VAChT over σ1 and σ2 receptors. In our previous 
paper, from the findings of in vitro binding assays, we suggested that OBDV would 
show comparably higher binding affinity to VAChT than to σ-1 and σ-2 receptors 
(Kozaka T et al., 2012). The current in vivo blocking evaluations also confirmed the 
affinity and selectivity of [77Br]OBDV binding for VAChT.  
The existence of highly polar radiolabeled metabolites in the brain can have a 
negative influence on VAChT imaging. Therefore, in vivo metabolism of [77Br]OBDV 
in the blood and brain of SD rats was examined at 60 min post-injection using TLC, 
where hexane: ethyl acetate: triethylamine (3:1:0.1, v/v/v) was used as mobile phase 
(Figure 24). In case of brain tissue, no indication of the presence of polar metabolite 
was observed on TLC. Most of the radioactivity in the brain tissue was unchanged with 
[77Br]OBDV, but only a polar metabolite of [77Br]OBDV was observed in the blood. 
This result specifies that the distribution of radioactivity in the rat brain at 60 min 
post-injection is only due to the radioactivity of [77Br]OBDV. The increased uptake of 
radioactivity in the pancreas or small intestine, even at 60 min post-injection, was 
assumed to be due to polar metabolites of [77Br]OBDV. Thus, this compound has 
suitable characteristics for the molecular imaging of VAChT in the brain. 
In the ex vivo autoradiograms [Figure 25(A)], it was observed that, at 30 min 
post-injection, [77Br]OBDV was accumulated in VAChT-rich regions of the rat brain, 
including the cerebral cortex, striatum, diagonal band, hippocampus, thalamus, 
amygdaloidal nucleus, cerebellum, and nuclei of cranial nerves. With a reference brain 
atlas, regions of interest (ROIs) were drawn over several brain regions to quantify of 
brain regional accumulation of [77Br]OBDV. Relative radioactivity concentration 
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(RRC) on the brain regions were measured by using image analysis software (Multi 
Gauge version 3, Fujifilm) and expressed as photostimulated luminescence (PSL)/area 
(mm2) (Table 5). A heterogeneous distribution pattern of the radioactivity was obtained 
with the highest level of radioactivity distribution in striatum. The regions including 
cerebral cortex, diagonal band, hippocampus, and posterolateral cortical amygdaloidal 
nucleus possess moderate radioactivity distribution and a low level of radioactivity 
accumulation was found in cerebellum. The brain regional biodistribution of 
[77Br]OBDV (table 4) almost accord with the RRC of the brain regions (table 5).  




The pattern of regional distribution of [77Br]OBDV, revealed from the ex vivo 
autoradiograms were in agreement with the distribution of VAChT-rich brain regions 
such as pre-synaptic cholinergic nerve terminals, as shown in the in situ hybridization 
histochemistry (ISHC) and immunohistochemistry (IHC) studies (Gilmor ML et al., 
1996; Ichikawa T et al., 1997; Schafer MK et al., 1995; Weihe E et al., 1996) as well as 
the brain regional accumulation of [125I]OIDV (Kozaka t et al., 2014). VAChT exists in 
the pre-synapse of cholinergic nerve systems (Clarke PB et al., 1984; Hulme EC et al., 
1990; Quirion R et al., 1993; Vilaro MT et al., 1993) and mediates the transportation of 
acetylcholine (ACh) to the cholinergic synaptic vesicles. ACh releases from presynaptic 
terminals into the synaptic cleft and binds with the acetylcholine receptors in 
postsynaptic terminals: muscarinic (M1-M5) and nicotinic receptors, and lead to a 
cholinergic responds. There are similarities in between the regional distribution of 
pre-synaptic cholinergic nerve terminals and acetyl choline receptors, situated at the 
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post-synapses of cholinergic nerve terminals. Muscarinic acetylcholine M1 receptors are 
found in high density in forebrain areas including the cerebral cortex, hippocampus and 
amygdala (David A., 1989). The muscarinic acetylcholine M2 receptor was present at 
high levels in the anterior and intralaminar nuclei of the thalamus, all motor nuclei of 
the cranial nerves (Allan IL et al., 1991) and granule and purkinjie cell layers of the 
cerebellum (Kozaka T et al., 2014). The M1, M2 and M4 muscarinic acetylcholine 
receptors are differentially localized in the striatum (Allan IL et al., 1991) and the 
diagonal band is a muscarinic acetylcholine M2–M5 receptor-abundant area (Kozaka T 
et al., 2014). The nicotinic receptor is widely distributed in the anteroventral nucleus of 
the thalamus (Rotter A et al., 1981). ISHC and IHC studies detect widely distributed 
VAChT-rich presynaptic cholinergic nerve terminals in various brain regions, including 
the cerebral cortex, striatum, diagonal band, hippocampus, thalamus, amygdaloidal 
nucleus, cerebellum, and nuclei of cranial nerves, which was also revealed in the 
autoradiographic study of [77Br]OBDV. So [77Br]OBDV can successfully visualize the 
VAChT rich regions, widely distributed throughout the whole rat’s brain . 
 The distribution of [77Br]OBDV was completely blocked by the co-injection 
of [77Br]OBDV with (+/-)-vesamicol, as an inhibitor, and no specific accumulation of 
the [77Br]OBDV was witnessed in brain sections [Figure 5(B)]. The uptake of 
[77Br]OBDV in cerebellum was observed in the autoradiogram. Both the in situ 
hybridization histochemistry (ISHC) and immunohistochemistry (IHC) have detected 
VAChT-positive neurons in the cerebellar cortex and cranial nerve nuclei (facial nucleus, 
trigeminal motor nucleus (Ichikawa T et al., 1997). The presence of 
VAChT-immunoreactive (VAChT-IR) axon terminals in cerebellar nuclei was also 
confirmed by IHC (Ichikawa T et al., 1997). Moreover, in the cerebellum, purkinje cell 
bodies contained VAChT mRNA and VAChT protein (Ichikawa T et al., 1997, Gilmor 
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ML et al., 1996). The accumulation of [77Br]OBDV was also observed in thalamus. In 
the thalamus, no VAChT- immunoreactive (IR) cell bodies were detected; however, 
VAChT-positive fibers were seen in most thalamic nuclei. Particularly high densities of 
VAChT-IR fibres were demonstrated in the anteroventral thalamic nucleus, whereas the 
other thalamic nuclei contained lower densities of VAChT-positive fibres (Arvidsson U 
et al., 1997). 
The cyclohexane ring in the decalin moiety of OBDV in comparison with 
vesamicol might affect binding to neuronal receptors by the increasing steric bulk 
(Kozaka T et al., 2014). 
Hence, because of the characteristic features of high lipophilicity, low affinity 
for σ-1 and σ-2 receptors and high selectivity for VAChT, in comparison with 
(+/-)-vesamicol and/or other vesamicol derivatives, Br-76 labeled OBDV, with a 
framework of DV and a halogen atom (-Br) at the ortho-position of the 
4-phenylpiperidine moiety, has the potentiality to be used as a promising PET VAChT 
imaging probe. 
6.3  Experimental 
6.3.1 Syntheses: 4-(2-Bromophenyl)piperidine (7), OBDV (8) and OTDV (9) were 
synthesized by following the already published (Kozaka, T. et al. Bioorg Med Chem., 
2012, 20, 4936-4941) synthetic route for compounds (7), (8), and (9). So same synthetic 
procedures and data of compounds (7), (8), and (9) of that published article were used 
in the dissertation. 
6.3.1.1 Synthesis of 4-(2-Bromophenyl)piperidine (7):  
A solution of o-bromobenzaldehyde (20.0 g, 108 mmol), ethyl acetoacetate 
(27.3 mL, 216 mmol), and piperidine (2.14 mL, 21.6 mmol) in EtOH (77.2 mL) was 
stirred for 15 h at room temperature. To the reaction solution was added 12 M NaOH 
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(360 mL) and EtOH (350 mL). The reaction mixture was refluxed for 4 h, cooled to 
room temperature, and the organic solvents removed. The residue was acidified with 
conc. HCl (450 mL) in an ice bath, extracted with AcOEt, washed with water and brine, 
and concentrated to dryness. The residue was transferred to a glass filter and washed 
with cold Et2O to obtain dicarboxylic acid 2 (23.9 g) as a white solid without further 
purification.  
The above 2 (23.9 g, 83.2 mmol) was dissolved in 28% ammonia solution (280 
mL) by heating, and then water was evaporated off under reduced pressure. The 
resulting residue was heated to 200 oC to melt for 6 h, cooled to room temperature, 
extracted with CH2Cl2, washed with Na2CO3 aq. and brine, concentrated to dryness, and 
washed with cold Et2O. BH3-THF (1.0 M THF solution; 208 mL, 208 mmol) was added 
drop wise to a solution of the crude cyclic imide in THF (166 mL) at 0oC under Ar. The 
reaction mixture was allowed to gradually reach room temperature and refluxed for 20 
h. conc. HCl aq (300 mL) was carefully added to the reaction mixture at 0oC. The 
reaction mixture was refluxed for an additional 20 h, neutralized with NaOH aq., 
extracted with AcOEt, washed with water and brine, and concentrated to dryness. 
Solvents were evaporated off. Et2O (1 L) was added to the residue at 0
oC. The resulting 
white precipitate was isolated by filtration and washed with cold Et2O to obtain 3 (12.4 
g, 48% from 1) as a white solid without further purification: 1H NMR δ 7.54–7.51 (m, 
1H), 7.28–7.26 (m, 2H), 7.07–7.00 (m, 1H), 3.21–3.17 (m, 2H), 3.10 (tt, 1H, J = 3.7, 
11.9 Hz), 3.10 (dt, 2H, J = 2.3, 11.9 Hz), 2.21– 2.19 (m, 1H), 1.87–1.83 (m, 2H), 
1.65–1.53 (m, 2H); EI MS m/z 240 (M+ +1, 85.3), 241 (M+, 73.6). (Kozaka et al., 2012)   
6.3.1.2 o-Bromo-trans-decalinvesamicol (OBDV) (8):   
A mixture of 3 (2.25 g, 9.36 mmol) and trans-decalin-2,3- oxide (2.14 g, 14.0 
mmol) in EtOH (9.4 mL) was refluxed for 20 h. The solvent was evaporated off. The 
  Chapter VI: Evaluations of radiobromine labeled decalinvesamicol derivative  
59 
residue was chromatographed on silica gel with hexane-AcOEt (5:1) to give 5 (2.10 g, 
57%) as a white solid: 1H NMR δ 7.54–7.52 (m, 1H), 7.30–7.25 (m, 2H), 7.06–7.02 (m, 
1H), 4.10–4.07 (m, 1H), 3.14–3.11 (m, 2H), 3.10 (tt, 1H, J = 3.4, 12.0 Hz), 2.33–2.30 
(m, 1H), 2.21–2.16 (m, 1H), 2.12–2.07 (m, 1H), 1.92–1.19 (m, 17H), 1.03–0.91 (m, 
2H); 13C NMR δ 144.9, 132.8, 127.6, 127.5, 127.3, 124.5, 67.0, 64.7, 52.9, 49.4, 41.8, 
36.7, 36.5, 35.9, 33.8, 33.7, 32.6, 32.5, 29.4, 26.6, 26.5; DART MS m/z 392 (M+ +1, 
50.8), 394 (M+ +1, 47.3). (Kozaka et al., 2012) 
6.3.1.3  o-Trimethylstannyl-trans-decalinvesamicol (OTDV) (9):  
A mixture of 5 (42.1 mg, 0.107 mmol), Pd(PPh3)4 (7.5 mg, 6.44 × 10
-3 mmol) 
and hexamethylditin (87.9 mg, 0.268 mmol) in anhydrous toluene (1.1 mL) was 
refluxed for 15 h under Ar. The solvent was evaporated off. The residue was 
chromatographed on silica gel with hexane-AcOEt (10:1) to give 6 (33.4 mg, 65%) as a 
white solid: 1H NMR δ 7.18–7.15 (m, 1H), 7.09–7.04 (m, 2H), 6.95– 6.90 (m, 1H), 
3.86–3.81 (m, 1H), 2.94–2.86 (m, 2H), 2.15–0.65 (m, 23H), 0.06 (m, 9H); 13C NMR δ 
153.02, 141.65, 135.95, 128.80, 125.79, 125.65, 66.94, 64.65, 53.11, 49.85, 47.21, 
36.62, 36.49, 35.85, 34.57, 34.54, 33.75, 33.62, 29.46, 26.55, 26.48, - 8.22; DART MS 
m/z 478 (M+ +1, 1). (Kozaka et al., 2012) 
6.3.2  Preparation of rat cerebral and liver membranes: 
All the performed animal experiments meet the criteria of the guidelines for the 
care and use of Laboratory Animals at the Takara-machi Campus of Kanazawa 
University. The cerebrum or livers of Sprague-Dawley rat (8 weeks, male, 250–300 g) 
were homogenized with a Teflon-glass homogenizer in ice-cold 0.32 M sucrose buffer 
(pH 7.8). The homogenate was centrifuged at 1000 × g at 4oC for 10 min. The resulting 
precipitate from the centrifugation was removed and the collected supernatant was 
centrifuged at 55000 × g at 4oC for 1 h. The resulting precipitate from the centrifugation 
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was resuspended in ice-cold water with a Teflon-glass homogenizer and again 
centrifuged at 55000 × g at 4oC for 1 h. The resulting pellets of rat cerebrum or liver 
were resuspended in an ice-cold buffer (50 mM Tris–HCl/0.32 M sucrose, pH 7.8) with 
a Teflon-glass homogenizer (Kozaka, T. et al. Bioorg Med Chem., 2012, 20, 
4936-4941). 
6.3.3 In vitro binding assay:  
6.3.3.1 VAChT 
For VAChT in vitro binding assay, (-)-[3H]Vesamicol (Kd = 7.40 nM) was 
used as a radioligand. Rat cerebral membranes was added to each ice-cold assay tube 
arranged in quadruplicate. Each of the assay tube contains (-)-[3H]vesamicol, DTG (0.2l 
M) to mask the σ receptors and the displacing ligands at various concentrations 
(1.0×10-10 – 10-5 M) in 50 mM Tris–HCl buffer (pH 7.8). The rat’s cerebral tissue was 
added to each assay tube on an ice bath, followed by the incubation of each reaction 
mixture in tubes at 37oC for 60 min, and then the reaction mixtures were quenched by 
cooling in an ice bath. Each sample of the assay tubes was treated with cell harvester 
and passed through glass-microfiber filters (Whatman, GF/F). The glass-microfiber 
filters were presoaked in 0.3% polyethyleneimine to reduce the non-specific binding. 50 
mM Tris–HCl (pH 7.8) was used as the washing buffer for the filters and the 
radioactivities of the filters were counted with a liquid scintillation counter (Aloka, 
LSC-5100). Three independent in vitro VAChT binding assays were carried out 
(Kozaka, T. et al. Bioorg Med Chem., 2012, 20, 4936-4941). 
6.3.3.2 σ-1 Receptor 
For the σ-1 receptor in vitro binding assay, (+)-[3H]Pentazocine (Kd = 19.9 
nM) was used as a specific radioligand. Rat cerebral membranes was added to each 
ice-cold assay tube arranged in quadruplicate. Each of the assay tubes contains 
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(+)-[3H]Pentazocine and the displacing ligands at various concentrations (1.0×10-10 – 
10-5 M) in 50 mM Tris–HCl buffer (pH 7.8). The rat’s cerebral tissue was added to each 
assay tube on an ice bath, followed by the incubation of each reaction mixture in tubes 
at 37oC for 90 min, and then the reaction mixtures were quenched by cooling in an ice 
bath. Each sample of the assay tubes was treated with cell harvester and passed through 
glass-microfiber filters (Whatman, GF/B). The glass-microfiber filters were presoaked 
in 0.3% polyethyleneimine to reduce the non-specific binding. 50 mM Tris–HCl (pH 
7.8) was used as the washing buffer for the filters and the radioactivities of the filters 
were counted with a liquid scintillation counter (Aloka, LSC-5100). Three independent 
σ-1 receptor in vitro binding assay were carried out (Kozaka, T. et al. Bioorg Med 
Chem., 2012, 20, 4936-4941). 
6.3.3.3 σ-2 Receptor 
For the σ-2 receptor in vitro binding assay, [3H]DTG (Kd = 22.3 nM) was used 
as a radioligand with (+)-[3H]Pentazocine to mask the σ-1 receptor. Rat cerebral 
membranes was added to each ice-cold assay tube arranged in quadruplicate. Each of 
the assay tubes contains [3H]DTG, pentazocine (1.0 μM), and the displacing ligands at 
various concentrations (1.0×10-10 – 10-5 M) in 50 mM Tris–HCl buffer (pH 7.8). The 
rat’s cerebral tissue was added to each assay tube on an ice bath, followed by the 
incubation of each reaction mixture in tubes at 37oC for 90 min, and then the reaction 
mixtures were quenched by cooling in an ice bath. Each sample of the assay tubes was 
treated with cell harvester and passed through glass-microfiber filters (Whatman, GF/B). 
The glass-microfiber filters were presoaked in 0.3% polyethyleneimine and washed 
with 50 mM Tris–HCl (pH 7.8). Radioactivities of the filters were counted with a liquid 
scintillation counter (Aloka, LSC-5100). Three independent σ-2 receptor in vitro 
binding assay were carried out (Kozaka, T. et al. Bioorg Med Chem., 2012). 
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6.3.4   Radiosynthesis and purification of [77Br]OBDV:  
o-trimethylstannyl-trans-decalinvesamicol (OTDV) was the main precursor for 
the synthesis of [77Br]OBDV. [77Br]OBDV was radiosynthesized by the tin-bromine 
exchange reaction from OTDV with no-carrier added [77Br]Br- (Specific activity: 2.0 
TBq/µmol), HCl and chloramine-T (Figure 22). The cyclotron facility of the biomedical 
imaging research center of Fukui University supplied no carrier added [77Br]Br-. Briefly, 
[77Br]Br-, (18.5 MBq/5~10 μL in EtOH) was added to a reaction vial containing OTDV 
(21.2 mM in EtOH, 50 μL), followed by the addition of 0.1 M HCl (50 μL) and aq. 
chloramine T (23.7 mM in H2O, 40 μL). The reaction mixture was shaken for 5 min at 
room temperature, followed by the incubation at 77oC for 30 min. With the addition of 
Na2S2O5 (15.8 mM in H2O, 20 μL) and 6M NH3 (100 μL, the reaction mixture was 
quenched. The unreacted water-soluble by products from the resultant mixture were 
removed by passing the reaction mixture through a Sep-Pack C-18 light column. The 
SEP-Pack C-18 light column was washed with an additional 15 mL H2O. The trapped 
[77Br]OBDV in the SEP-Pack C-18 light column was then eluted with 5 mL EtOH and 
the collected eluent was concentrated by heating under N2. [
77Br]OBDV was purified 
with reversed phase HPLC at a flow rate of 4.0 mL/min with a mobile phase of 
acetonitrile: H2O: monoethanolamine (90:10:0.2, v/v/v) at 40°C. The reversed phase 
HPLC was equipped with a Zorbax-ODS RX-C18 column (9.6 mm × 250 mm). 
Ultraviolet (UV) absorption was monitored at 230 nm. The chemical identity of 
[77Br]OBDV was confirmed by co-injection with the reference OBDV on HPLC under 
same conditions. 
During the purification of [77Br]OBDV with HPLC, the chemical amount of 
[77Br]OBDV in the injected volume of [77Br]OBDV is lower than the minimum 
detectable limit of UV detector at 230 nm, with which reference OBDV was detected. 
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So, 300 μL of each of the different concentrations (103 μM ~ 10-5 μM) of reference 
OBDV were injected in the HPLC under the same conditions to determine the 
minimum detectable concentration of reference OBDV. 0-1 μM of OBDV was found to 
be the minimum detectable concentration of reference OBDV with the HPLC at 230 nm 
and mass of the reference OBDV was calculated. Then the radioactivity of 300 μL of 
pure [77Br]OBDV was also recorded and the specific activity (SA) of [77Br]OBDV was 
measured. 
6.3.5 In vivo biodistribution 
All the animal experiments were carried out in accordance with the Guidelines 
for the Care and Use of Laboratory Animals at the Takara-machi Campus of Kanazawa 
University. To perform the in vivo biodistribution studies, Sprague-Dawley (SD) rats (8 
weeks, male, 250-300 g, n = 4 in each group) were intravenously injected 0.129 MBq 
(317.7 fmol) of [77Br]OBDV in 400 μL of 5% ethanol/saline solution (v/v) via the tail 
vein. At 2, 30 and 60 min post-injection, the rats were sacrificed by decapitation under 
anesthesia with diethyl ether and blood samples were collected. The removed brain was 
immediately placed on ice and dissected into four segments: cerebral cortex, striatum, 
cerebellum, and the rest of the brain. The brain regions, blood, urine, and the organs of 
interest (heart, lung, liver, spleen, pancreas, stomach, small intestine, kidney and 
bladder) were collected and weighed. The radioactivities of all the harvested organs, 
brain regions, blood, and urea were measured with an auto well gamma system 
(AccuFLEX γ7010; Aloka). Data were calculated as the percent of injected dose per 
gram of tissue (% ID/g). 
6.3.6 In vivo blocking studies 
To evaluate the specific uptake of [77Br]OBDV, receptor blocking experiments 
were performed. Randomly divided four groups of SD rats (8 weeks, male, 250-300 g, 
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n = 4 in each group) were injected with 0.111 MBq (273.4 fmol) of [77Br]OBDV in 400 
μL of 5% ethanol/saline solution (v/v) intravenously via the tail vein with 0.250 µmol 
(+/-)-vesamicol, 0.250 µmol [(+)-3-PPP], 0.250 µmol (+)-pentazocine, and none as a 
control. The rats were sacrificed at 30 min post-injection by decapitation under 
anesthesia with diethyl ether and blood samples were collected. The brain was removed 
and immediately placed on ice and dissected into segments consisting of 4 parts 
(cerebral cortex, striatum, cerebellum, and the rest). The four dissected brain parts were 
collected and weighed. The radioactivity of each part was measured with an auto well 
gamma system (AccuFLEX γ7010; Aloka). Analysis of the data of the data from the 
blocking studies were performed using a one-way ANOVA followed by a Tukey’s 
multiple comparison test (GraphPad Prism Version 4 software). Differences were 
considered significant when P < 0.05. 
6.3.7 In vivo metabolite analysis 
In vivo metabolite analysis with [77Br]OBDV was performed by the 
autoradiographic analysis of thin layer chromatography (TLC). The SD rats 8 weeks, 
male, 250-300 g, n = 3) received intravenous injection of of 0.400 MBq (985.2 fmol) of 
[77Br]OBDV in 400 μL of 5% ethanol/saline solution (v/v) via the tail vein. The rats 
were sacrificed at 60 min post-injection by decapitation under anesthesia with diethyl 
ether and blood samples were collected in a heparin-coated tube. The brain was 
removed, immediately place on ice and the brain segments were harvested without the 
cerebellum. The blood corpuscle are separated by centrifugation at 15000 rpm for 15 
min at 4oC. The resulting plasma (300 μL) was separated from the involved 
macromolecules (>10000 molecular weight) by ultrafiltration. The resulting filtrates 
was analyzed by TLC using mobile phase of hexane: ethyl acetate: triethylamine 
(3:1:0.1, v/v/v). The brain tissue was homogenized for 1 min with an ultrasonic 
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homogenizer for 1 min with an ultrasonic homogenizer in acetonitrile and H2O (2:1). 
The brain homogenate suspensions were centrifuged 20000 × g for 20 min at 4 oC. The 
supernatant was collected and separated from the involved macromolecules (>10000 
molecular weight) by ultrafiltration. The resulting filtrate was analyzed by TLC using 
mobile phase of hexane: ethyl acetate: triethylamine (3:1:0.1, v/v/v). The TLC plates 
were then exposed to an imaging plate (BAS-IP SR 2025; Fujifilm) for 5 days (120 hrs), 
after which the plates were scanned by a BAS-5000 phosphoimager (Fujifilm). 
6.3.8 Determination of partition coefficient: 
The partition coefficient (log Po/w) of [
77Br]OBDV was determined by the 
standard method using n-octanol and 0.1 M phosphate buffer (pH = 7.4). Briefly, 
[77Br]OBDV was mixed with n-octanol (15 mL) and 0.1 M phosphate buffer (15 mL), 
in each 50 mL centrifuge tube (where, n = 4). Then the mixture was vortexed for 5 min, 
followed by centrifugation of the mixture at 1000 × g for 10 min. After centrifugation, 
1mL n-octanol and 1 mL phosphate buffer were separately transferred to the 
polyethylene tube from each centrifuge tube in quadruplicate. The radioactivity of the 
each tube was measured with an auto well gamma system (AccuFLEX γ7010; Aloka). 
The partition coefficient was calculated with the formula: log Po/w = log10 Co/Cw 
(radioactivity in n-octanol layer/radioactivity in aqueous layer).  
6.3.9 Ex vivo autoradiography 
In ex vivo autoradiography, 1.00-1.58 MBq (2.46-3.89 pmol) of [77Br]OBDV 
in 400 μL of 5% ethanol/saline solution (v/v) was intravenously injected (8 weeks, male, 
250-300 g, n = 3) via the tail vein with 0.250 μmol (+/-)-vesamicol, and none as a 
control. The rats were sacrificed by decapitation under anesthesia with diethyl ether at 
30 min post-injection and blood samples were collected. The whole brain was harvested 
and immediately frozen in Tissue-Tek O.C.T. Compound (Sakura Finetek) at −78 oC. 
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The frozen brain was cut into 20-μm-thick horizontal slices at −20 °C using a cryostat 
microtome (HM 525 Cryostat; Thermo Scientific) and mounted on glass slides. The 
slices were then exposed to an imaging plate (BAS-IP SR 2025; Fujifilm) for 2 days, 
after which the plates were scanned with a BAS-5000 phosphoimager (Fujifilm).  




PART A: Evaluation of Tacirine derivatives as HAChT imaging probes 
In an effort for the development of tacirine and its 2-oxo-1-pyrilidineacetyl 
derivatives as HAChT imaging probe, tacirine, DMTA (2,3-dimethylfuran derivative of 
tacirine) and their corresponding 2-oxo-1-pyrrolidineacetyl derivatives, namely PTAA 
and MKC-231, was synthesized and the binding affinities of these derivatives for 
HAChT were evaluated through in vitro HAChT [3H]HC-3 competitive binding assay. 
No affinity towards HAChT of the synthesized compounds was revealed from the In 
vitro binding assay. 
Hemicholinium-3 is a competitive inhibitor of the HACU system and it is 
worthy to do further research works for the development of radiolabelled HC-3 
derivatives with high affinity for HAChT, which can diffuse the BBB, to enable the in 
vivo investigation of HACU system. It is also worthy to do more extensive review to 
develop an effective in vitro HAChT [3H]HC-3 competitive binding assay protocol and 
the protocol for the preparation of brain homogenate, used in the in vitro HAChT 
[3H]HC-3 competitive binding assay. 
 
PART B: In vivo evaluation of radiobromine labelled decalinvesamicol analogue as 
VAChT imaging probe. 
Radiosynthesis of [77Br]OBDV was performed with moderate radiochemical 
yield and the radiochemical purity of [77Br]OBDV was > 99%. The specific activity of 
[77Br]OBDV was found to be 322 ~ 406 GBq/μmol. After the intravenous injection in 
the rat’s tail vein, [77Br]OBDV readily crossed the BBB and accumulated throughout 
the whole brain with the highest accumulation in the striatum in the rat brain followed 
by the cerebral cortex and cerebellum. Rapid penetration through BBB of [77Br]OBDV
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is also an indication of the lipophilicity of the tracer which is very important for 
neuroimaging radioligand. Significant inhibition of the in vivo accumulation of 
[77Br]OBDV in rat brain with the co-injection of [77Br]OBDV and 0.250 μmol of 
(+/-)-vesamicol revealed the affinity of [77Br]OBDV for the binding sites of VACT. On 
the other hand, no significant inhibition of the accumulation of [77Br]OBDV with the 
con-injection of [77Br]OBDV and 0.250 μmol of (+)-pentazocine or (+)-3PPP revealed 
the selectivity of [77Br]OBDV over sigma receptors, which is in accordance with the 
previously reported in vitro binding assay of OBDV. Ex vivo autoradiography revealed 
that [77Br]OBDV accumulated in the corresponding VAChT-rich regions in the rat brain 
including the cerebral cortex, striatum, diagonal band, hippocampus, thalamus, 
amygdaloidal nucleus, cerebellum, and nuclei of cranial nerves. The distribution pattern 
of relative radioactivity concentration (RRC) of [77Br]OBDV in rat’s brain regions was 
found heterogeneous, with the highest level in the striatum. On the other hand, no 
specific brain regional accumulation was observed, when [77Br]OBDV was co-injected 
with (+/-)-vesamicol. Hence, on the basis of the findings of in vivo evaluations of 
[77Br]OBDV, it can be concluded that [76Br]OBDV has the potential to be a prospective 
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Figure 33 (b): 13C NMR Spectra of OTDV. 
OTDV (9) 
